Parkland

Board of Managers

Agenda for the ***Board of Managers*** meeting of the Dallas County Hospital District is scheduled for ***Wednesday, February 25, 2026, at 12:50 PM (or immediately following HOMES meeting)*** at 5200 Harry Hines Blvd (WISH Building), Dallas, TX 75235, Conference Room 02-175. (If assistance is needed in locating the room, please see the Administration receptionist on the 4th floor, 04-131.) Videoconferencing access is also possible via Webex. That application is available at https://www.webex.com/downloads.html. Teleconferencing access is possible by calling +1-415-655-0001. Both virtual access forms require inputting (meeting number: 2307 937 7638; meeting password: 1234) to join the meeting. The ***Board of Managers*** reserves the right to exercise discretion and may convene in Executive Session as permitted by Texas Government Code §§551.071 (consultation with attorney), 551.072 (deliberations regarding real estate), 551.074 (personnel matters), 551.076 (deliberations regarding security devices or security audits), 551.078 and/or 551.0785 (deliberations by medical committee or by governmental body that administers a public insurance, health or retirement plan regarding individuals' medical or psychiatric records), 551.085 (deliberation by governing board of certain providers of health care services), 551.087 (deliberation regarding economic development negotiations), 551.088 (deliberation regarding test item); Texas Government Code §418.183 (deliberation of information under §§418.175 – 418.182 for purposes of disaster management or disaster planning); Texas Health & Safety Code §161.032 (medical committee or medical peer review committee records, information or reports; and/or medical committee or medical peer review committee proceedings under Tex. Health & Safety Code Chapter 161 and/or Tex. Occ. Code Chapters 151 and 160); and/or as otherwise authorized by law on any item listed below. The ***Board of Managers*** may consider any of the agenda items in open or executive session and may continue the meeting as necessary to accomplish the business at the time and place designated by the Chair to reconvene.

	PAGE	TIME (MIN)	PRESENTER(S)
I. Opening/Call to Order/Determine the Presence of a Quorum Present/Mission Statement/Opening Remarks ***Advance Wellness | Relieve Suffering | Develop and Educate*** **I CARE** **I**ntegrity **C**ompassion and Collaboration **A**ccountability **R**espect **E**quity The agenda has been developed by the Chief Governance Officer in consultation with the Board Chair and reviewed and affirmed by Counsel.			Chair
A. Invocation by Chaplin Javeria Paloba		5	
B. Public Comments Regarding Agenda Items See public comment registration information and rules at *https://www.parklandhospital.com/board-of-managers*			
II. Consent Agenda: Minutes			Chair
A. Consideration and Appropriate Action Regarding Minutes 2026-01-14 Facilities Committee			
B. Consideration and Appropriate Action Regarding Minutes 2026-01-14 Audit Committee			
C. Consideration and Appropriate Action Regarding Minutes 2026-01-27 Budget & Finance Committee			
D. Consideration and Appropriate Action Regarding Minutes 2026-01-27 Quality of Care & Patient Safety Committee			
E. Consideration and Appropriate Action Regarding Minutes 2026-01-27 Board of Managers			
F. Consideration and Appropriate Action Regarding Minutes 2026-01-30 Talent Development and Executive Compensation Committee			

	PAGE	TIME (MIN)	PRESENTER(S)
III. Consent Agenda: Contracts			Chair
A. Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**			
IV. Consent Agenda: Policies			Chair
A. Consideration and Appropriate Action Regarding Fiscal 8311-1-20 Retirement Plan Funding Policy			
V. Consent Agenda: Other			Chair
A. Consideration and Appropriate Action Regarding Parkland's PCCI Board of Directors Reappointment of Dick Daniels			
VI. Consent Agenda: Patient Settlements			
A. Consideration and Appropriate Action Regarding Patient Settlements			Chair
VII. Consent Agenda: Medical Executive Committee Items			Chair
A. Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers			
VIII. Reports Requiring Deliberation(s) and/or Possible Action			
A. CEO Update on System Operations		15	Fred Cerise, MD
B. FIFA Update and Disaster Management Presentation		20	Marshal Isaacs, MD
C. Governance Update and Discussion Regarding Key Upcoming Dates and Board Committee Appointments		10	Chair
IX. Break			
X. Executive Session			
A. Discussion Regarding Potential New Service Lines and Property Acquisition *Tex. Gov't Code §551.072, §551.085*		40	Fred Cerise, MD
B. Consultation with Attorney on Risks Identified and Considered by the Governance, Compliance and Ethics Committee in the Quarterly Report on Open Compliance Reviews Covered in their February 11, 2026 Meeting *Tex. Gov't Code 551.071*		20	Brad Nitschke, JD
XI. Executive Session – Possible Deliberation			
A. Possible Deliberation Regarding Medical Executive Committee Credentialing Report Tex. Health & Safety Code §161.032			
B. Possible Deliberation Regarding Delineation of Privileges Internal Medicine – Nephrology Tex. Health & Safety Code §161.032			

	PAGE	TIME (MIN)	PRESENTER(S)

C. Possible Deliberation Regarding Delineation of Privileges
OB/GYN Tex. Health & Safety Code §161.032

D. Possible Deliberation Regarding Delineation of Privileges
Hematology & Medical Oncology
Tex. Health & Safety Code §161.032

E. Possible Deliberation Regarding Patient Settlements
Tex. Gov't Code §551.071

XII. Reports Requiring Deliberation(s) and/or Possible Action — Chair

A. Possible Deliberation Regarding Board of Managers Attendance Report

B. Possible Deliberation Regarding Board of Managers Meeting Evaluation Report

XIII. Action Items — Chair

A. Board May Take Action on Any Agenda Item(s) Above

XIV. Adjourn — Chair

A. Closing Remarks

B. Call to Adjourn

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									February 25, 2026
				Medical Products and Services					
M1	Expense	Mod # 1 Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents	Becton and Dickinson and Company	3/20/2023 - 3/19/2028	$85,000	$201,000	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Microbiology
M2	Expense	Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems	Biomet Microfixation, LLC	2/25/2026 - 2/24/2029	$850,000	$850,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan/Periop Services
M3	Expense	Coronary Stents and Accessories	Boston Scientific	3/1/2026 - 2/28/2031	$2,250,000	$2,250,000	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Cardiac Cath Lab
M4	Expense	EchoTip Insight Portosystemic Pressure Gradient Measuring System	Cook Medical, Inc	2/25/2026 - 2/26/2031	$350,000	$350,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan/Periop Services
M5	Expense	Mod # 1 Adding Additional Funding for Genetic Testing Services through Exact Sciences	Exact Sciences Laboratories, LLC	1/29/2024 - 2/28/2027	$170,000	$420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Microbiology

M6	Expense	Mod # 1 Add Funding for Genetic Testing through Foundation Medicine Inc.	Foundation Medicine Inc.	3/28/2024 - 4/30/2026	$150,000	$500,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services
M7	Capital	Cardiac Stress Systems	GE Healthcare	3/6/2026 - 3/5/2027	$222,824	$222,824	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M8	Expense	Mod # 3 Neurosurgical Implants	Integra LifeSciences	1/1/2021-12/31/2027	$1,401,000	$4,420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Surgical Services Administration
M9	Expense	Mod # 1 One Year Contract Extension for OCD Diana Reagents	Polymedco Cancer Diagnostic Products, LLC	3/1/2023-2/28/2027	$270,000	$874,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tim Lenz/Laboratory Services - Pathology
M10	Expense	Mod # 1 Neurovascular Implants	Stryker Neurovascular	1/1/2019-12/31/2026	$361,000	$2,646,100	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M11	Expense	Mod # 5 Biotel Emergency Medical Services	The University of Texas Southwestern Medical Center	10/16/2016-9/30/2026	$134,480	$583,714	Contract Extension without Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Melody Gardner and Courtney Edwards/Biotel Department
M12	Expense	Mod # 1 On-Call Coverage for Patient Safety Officer and Clinical Post Transplant Coordinator Services	Transplant Coordinators of America	7/1/2021-6/30/2026	$219,000	$919,000	Sole Source Modification	Yes	Linda Kautzman
M13	Expense	Signatera Genetic Test	Natera	2/27/2026 - 2/26/2029	$537,000	$537,000	Sole Source	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Referral Lab
M14	Expense	Mod # 1 Request Additional Funds for Blood and Blood Products	BloodSolutions, LLC dba Bloodbuy	3/7/2022-Evergreen	$250,000	$446,000	Sole Source Modification	Yes	Tim Lenz/Amy Sigman/Laboratory Services - Transfusion Services
M15	Capital and Expense	Alaris Pump Modules, and associated software	BD CareFusion	2/25/2026 -1/31/2028	$843,880	$843,880	GPO Purchase	Yes	Patrick Eaton/ Clinical Engineering
				Construction and Facilities					
C1	Capital	Central Utility Plant (CUP) Boiler Burner Replacement	Burner Combustion Systems LLC	2/26/2026 - 8/25/2026	$414,030	$414,030	Invitation for Bids	Yes	David Alvarez/Engineering Services
C2	Revenue: Court Approval	Eleventh Amendment to Lease Agreement	The Board of Regents of the University of Texas System for the use and benefit of the University of Texas Southwestern Medical Center at Dallas	4/1/2008-3/31/2031	$126,737	$1,233,067	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Beall Carothers/Planning Design & Construction

Information Technology									
IT1	Expense	Bryte Assistive AI SaaS for UKG Pro WFM	UKG Kronos Systems LLC	3/1/2026 - 2/28/2029	$867,000	$867,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Deborah Johnson/Information Technology
Hospital Operations									
O1	Expense	Mod # 1 Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) - External Audit	Health Information Associates	5/1/2025-4/30/2028	$80,000	$2,570,440	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Mandy Transou/HIM Coding Integrity
O2	Expense	Mod # 1 Consulting Services for Affordable Care Act (ACA) Exchange	Milliman, Inc.	11/1/2024-11/31/2026	$1,600,000	$2,890,000	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristin Alvarez/Value Based Care
Ratification/Deviation/Informational Only									
D1	Expense-Approved Deviation	Consulting Services for Children's Health Impact Assessment & Improvement Actions, and Parkland Health Plan Contribution Margin Improvement.	Shara McClure Health Solutions	2/13/2026 - 8/12/2026	$650,000	$650,000	Sole Source	Yes	Edmundo Castaneda/Administration

Invocation

Consideration and Appropriate Action Regarding Minutes 2026-01-14 Facilities Committee

Minutes of the Facilities Committee Development meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, January 14, 2026, scheduled for 11:30 a.m. in the WISH Building Conference Room (02-175) at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Vincent Hall noted that a quorum was physically present and called the meeting to order at 11:31 a.m. Committee members Todd Furniss, JD, Farida Minner, RN, Reina Gonzalez, JD, and Eric G. Bing PhD, MD, attended in person.

Board Member attendees included: Marjorie Petty, JD and Elizabeth Palacios

Staff Present (via Webex and in-person) included:

Beall Carothers, Director of Planning, Development & Construction
Bennie Miller, Mgr., Supplier Diversity
Brad Nitschke, Interim Chief Legal Officer
Donna Richardson, EVP & Chief Nursing Officer
Edmundo Castañeda, EVP & Chief Operating Officer
Fred Cerise, Chief Executive Officer
Guy Toliver, Dir. Inclusion-Supply Diversity
John Wilson, Director/PDC
Kareem Abdelfattah, ACMO
Lance Mendiola, VP Construction Facilities & Real Estate
Morgan Simmons, Governance Program Coordinator
Pamela Bryant, SVP & Chief Supply Chain Officer (via Webex)
Samia Zia, Director Strategy
Saul Cordero, SVP & Chief Governance and Strategy Officer

Other attendees:
Kristen Harrison - SmithGroup

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Facilities Minority and Women-Owned Business Enterprises (MWBE) Report

Benne Miller provided the MWBE Report. He reported on MWBE participation percentages for Construction Contracts over $200,000 for all projects active in FY25. Next, he reported on MWBE participation percentages for Professional Services Contracts over $200K. Lastly, he presented MWBE participation percentages for Goods/Equipment Contracts over $200K.

The Committee asked questions and received further information related to the MWBE Report.

B. Update and Report on Current FY26 Facilities Projects

Lance Mendiola presented the FY26 Projects. He reviewed the projects and provided an update on the status of each.

1. **Richland** Clinic Replacement
2. **Parkland Campus** - OK Paper Warehouse Demolition & Surface Parking
3. **Parkland Campus** – Moody Outpatient Center - Flexible Sigmoidoscopy Room Buildout and Equipment
4. **Parkland Hospital** – ACH 8th and 9th Floor Shell Buildout
5. **Parkland Hospital** - Emergency Department Triage Expansion
6. **Garland Health Center** – Community Oriented Primary Care (COPC) – Phase III Specialty and Optometry Expansion`
7. **Parkland Hospital** – Interventional Radiology Expansion Rooms 5&6
8. **Parkland Hospital** – Lab Consolidation
9. **Irving Health Center** - Community Oriented Primary Care (COPC) Renovation of Optometry Lane Expansion
10. **Garland Medical Plaza III** – Garland Plaza III Third Floor ARC and Podiatry
11. **Parkland Hospital** – Cardiac EP Lab Shell Buildout
12. **Parkland Campus** – Pediatric Behavioral Health Center Renovation
13. **Parkland Campus** - Redfield Parking Lot Improvements
14. **Parkland Hospital** – Butler Street Childcare Center Playground
15. **Inland Port**
16. **Southeast**

Lance Mendiola reported progress across multiple capital projects, beginning with the Richland Clinic, where permit reviews are underway with the City of Dallas and site preparation is expected to begin soon. He noted plans for a community and donor event once construction is ready to proceed. The OK Paper demolition and parking lot work are 10–15% complete, with added costs tied to delays and city requirements. Several clinical buildouts—including flexible sigmoidoscopy, Level 8–9 expansions, emergency triage, and optometry—are progressing on schedule. He also detailed ongoing interventional radiology expansion efforts, validated budgets, and anticipated completions aligned with operational needs.

C. Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**

Vincent Hall prompted the Committee to discuss and consider contracts for over $200,000. These contracts will proceed with the committee's recommendation to the Budget & Finance Committee.

The Committee asked questions and received additional information related to the consideration of contracts over $200,000.

Vincent Hall asked for a motion to approve contracts over $200,000. Todd Furniss motioned for approval. Farida Minner seconded. The motion carried unanimously.

VI. Executive Session

At 12:04 p.m., the Board entered Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

A. Report and Discussion Regarding Potential Purchase and Sale of Property

B. Consultation with Attorney Regarding Requirements Related to Committee Oversight of Minority and Women-Owned Business Enterprises (MWBE) in Facilities Projects

At 12:20 p.m., the Board moved back into Open Session.

VII. Adjourn

With no further business to discuss, the Committee Chair adjourned the meeting at 12:20 p.m.

SO RECORDED:

Vincent Hall	Brad Nitschke, JD
Committee Chair	Assistant Secretary

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									January 28, 2026
C2	Capital	Mod # 1 Big OK Paper Parking Lot Improvements.	Gilbert May, Inc. d/b/a Phillips May Corporation	4/24/2024-7/15/2026	$320,160	$4,313,463	Non-Sole Source Modification	Yes	Paul Woodard/Parkland Design and Construction
C3	Expense: Court Approval	Mod # 3 Amendment to Lease Agreement – DHA Lakewest Clinic	Housing Authority of Dallas	1/2/2017-1/1/2031	$254,794	$742,554	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Beall Carothers/Planning Design & Construction

Consideration and Appropriate Action Regarding Minutes 2026-01-14 Audit Committee

Minutes of the Audit Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, January 14th, 2026, scheduled for 10:00 a.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Todd Furniss, JD, noted that a quorum was physically present and called the meeting to order at 10:00 a.m. Committee members Yasmin Simon, JD, Elizabeth Palacios, MD, and Reina Gonzalez, JD attended in-person.

Board Member attendees included: Vincent Hall and Marjorie Petty, JD

Staff Present (via Webex and in-person) included:

Amy LaBarge, SVP & Chief Audit Officer
Andrea Claire, Mgr., Internal Audit
Brad Nitschke, Interim Chief Legal Officer
Donna Richardson, SVP & CNO
Edmundo Castaneda, EVP & COO
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Kareem AbdelFattah, ACMO
Keri Disney-Story, VP/Clinical Finance
Marsha Beasly, Chief Financial Officer Parkland Foundation
Michael Horne, President & CEO Parkland Foundation
Morgan Simmons, Board Governance Program Coordinator
Pam Bryant, SVP & Chief Supply Chain Officer
Saul Cordero, SVP & Chief Governance and Strategy Officer
Richard Humphrey, EVP & CFO

Other Attendees:
Chris Clark, FORVIS-MAZARS
David Harwood, FORVIS-MAZARS

II. Mission Statement

The Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Parkland Foundation Independent Auditors' Report Financial Statements September 30, 2025 and 2024

Lori K. Orta reported that the audit resulted in a clean, unmodified opinion, noting auditors are responsible only for the opinion itself and that management met all requirements for access, internal controls, and GAAP/GASB compliance. Key estimates included allowance for doubtful accounts, cost allocations, and in-kind contributions totaling $4.5M. She highlighted large donations creating concentration disclosures, no audit difficulties or disagreements, and no corrected or uncorrected misstatements for the year.

B. DCHD Parkland Health Financial Statement Audit, Fiscal Year 2025

Lori K. Orta reviewed the Foundation's financial statements, noting total assets of $49.6 million, primarily impacted by changes in long-term pledges receivable. She reported a $400,000 decrease in refundable liabilities as conditional gifts were recognized, and minor variances in amounts due to Parkland. Total net position increased to $48 million from $43 million. Revenues reached $23 million, driven by major contributions, while expenditures totaled $18 million, largely supporting patient services. Functional expenses showed 71% programmatic spending, resulting in a $4.5 million net position increase.

C. DCHD Retirement Income Plan, Results of the 2024 Financial Statement Audit, December 31, 2024, DCHD Supplemental Retirement Plans, Results of the 2024 Combined Financial Statement Audit, December 31, 2024

David Harwood reported that audit procedures were completed and draft financials distributed, with an unmodified, clean opinion expected. He noted no material weaknesses or internal control issues and described ongoing testing for the federal and state grant compliance audit, which is expected to conclude before the manager's upcoming leave. David highlighted changes in audit coordination due to new accounting leadership and an accelerated audit timeline, commending strong communication and smooth collaboration with management. Significant audit focus areas included third-party reimbursements, patient receivable allowances, health and workers' compensation liabilities, property taxes, and pension liabilities, many requiring actuarial or specialist expertise. He noted one audit adjustment related to patient receivable classifications but emphasized overall accuracy of financial reporting.

David summarized key financial trends, including increased patient revenue, strong net position growth, and nearly $1 billion in asset expansion over five years, while acknowledging Parkland's unique operational challenges.

D. Internal Audit Annual Performance Report, Fiscal Year 2025

Rick Humphrey reviewed a requested slide his team created regarding plan valuation and funded status. Rick explained how the plan's funding status is calculated by comparing total assets to the actuarially determined liability, which reflects future benefits discounted at an assumed 6% return. He reviewed the history of lowering the discount rate from 8.5% to 6% and noted that using the consistent 6% rate shows the plan was 54% funded historically, improving to 73% before plateauing. He emphasized the significance of this more accurate measure for understanding pension obligations and guiding future capital allocation decisions.

Next, Amy LaBarge reported that Internal Audit completed 85% of its annual audit plan despite a 25% vacancy rate. She noted that 61% of follow-up items were closed and fraud procedures were incorporated across all audits. She reviewed the recent external quality assurance review, internal time allocation shifts, and a minor financial deficit driven by unbudgeted peer reviews. Amy also outlined organizational restructuring, strong engagement results, and upcoming priorities focused on audit quality, technology use, talent development, and enhanced performance measurement.

A. Open Session Summary to discuss the following topics:

i. Overview of the progress on Parkland's 2026 Audit Plan

Amy mentioned that the Audit Plan for 2026 will show two Audits closing in January 2026 thus far. Many of these audits will be ongoing through the beginning of February. Amy mentioned there may be an edit to the plan for 2026 due to the hiring freeze due to WorkDay implementation at Parkland.

ii. Revenue Cycle - Professional Billing Post Implementation Audit, Report No. 25-03

Amy reviewed the professional billing audit, mentioning that the objective was to evaluate the billing process within the EPIC software specifically assessing its performance and functionality with regulatory requirements.

iii. Physical Inventory - Fiscal Year 2025 Audit, Report No. 25-19
Amy discussed the inventory audit with the committee and mentioned an overall pharmacy inventory counting error rate of 9% within the allowable error rate of 10%. The overall error rate for supply chain was 1%, which is within the 5% limit.

iv. Follow Up Report Status – Open Session
No audits or issues were closed during the period and no action due date change requests were received.

VI. Executive Session

At 10:55 a.m., the Committee moved into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics as necessary.

E. Executive Session Summary to discuss following topics:
Tex. Health & Safety Code §§161.032 & 161.0315 and *Tex. Occ. Code* §160.007

i. Follow-up Report Status – Executive Session
Update on corrective action plans for audits presented in prior executive session Audit Committee meetings.

F. Discussion regarding report and/or information provided by the Chief Audit Executive and related items on this agenda.
Tex. Health & Safety Code §§161.032 & 161.0315 and *Tex. Occ. Code* §160.007.

G. Consultation with Attorney
Tex. Gov't Code § 551.071.

i. Review of Open Litigation, Claims, and Settlements
(See Attached List)

Chair adjourned Executive Session and moved into Open Session at 11:12 am.

The Chair, Todd Furniss, asked for follow-up items from the committee. None were mentioned.

VII. Action Items

A. Committee may take action on any agenda item(s) above.

VIII. Adjourn

With no further business to discuss, the Committee Chair entertained a motion to adjourn the meeting at 11:12 a.m.

SO RECORDED:

Todd Furniss, JD Committee Chair	Brad Nitschke, JD Assistant Secretary

Active Litigation Matters, December 2025

Construction Cleaning, Inc. v. Dallas County Hospital District
Cause No. CC-24-02035-C, In the County Court at Law No. 4, Dallas County, Texas

Dallas County Hospital District v. Haley Burr, et. al.
Cause No. DC-23-20781, In the 101st District Court, Dallas County, Texas

Dallas County Hospital District v. Shiftwise, Inc., et. al.
Cause No. DC-25-10545, In the 68th Civil District Court, Dallas County, Texas

Paul Aaron French a.k.a. Michael Vega v. Dallas County, et al.
Cause No. 3:22-CV-02702-E, In the US District Court, Northern District of Texas, Dallas Division

Hyde, Jason J. v. Dallas County, et al.
Cause No. DC-24-18636, In the 134th District Court, Dallas County, Texas

Lewis, Shamond v. Dallas County, et al.
Cause No. 3:23-CV-00381-D, In the US District Court, Northern District of Texas, Dallas Division

Oludele Oladoja v. Dr. Zia Rehman
Cause No. 3:24-CV-02709-K-BN, In the US District Court, Northern District of Texas, Dallas Division

US ex rel Chase v. UT Southwestern Medical Center, Parkland Health & Hospital System, et. al.
Cause No. 5:23-cv-00381-JKP, In the US District Court, Western District of Texas, San Antonio Division

Dallas County Hospital District v. BARA, a Joint Venture
Cause No. DC-24-01577, In the 192nd District Court, Dallas County, Texas

Alejandrino Lopez v. Dallas County Hospital District d/b/a Parkland Health System d/b/a Parkland Memorial Hospital
Cause No. 4:25-CV-568, In the US District Court, Eastern District of Texas, Sherman Division

Angelica Reyna v. Parkland Health & Hospital System
Cause No. CC-24-08776-C, In the County Court at Law No. 3, Dallas County, Texas

Brandon Norwood v. Dallas County Hospital District
Cause No. 3:23-CV-01490-S, In the US District Court, Northern District of Texas

Alvah Johnson, Michael Pierce and Theodore Bramble v. Dallas County Hospital District
Cause No. 3:23-CV-01574-N, In the US District Court, Northern District of Texas

Edrise Newton v. Dallas County Hospital District d/b/a Parkland Health & Hospital System
Cause No. 3:24-CV-3008, In the US District Court, Northern District of Texas, Dallas Division

Giovonni Shelton v. Parkland Health
Cause No. 3:24-CV-2190, In the US District Court, Northern District of Texas, Dallas Division

Christopher Jordan Horn v. Kristi Tillery
Cause No. JPC-25-01010-22, In the Justice Court Precinct 2, Place 2 Dallas County, Texas

Kiana Johnson v. Dallas County Hospital District
Cause No. CC-24-01307-B, In the County Court at Law No. 2, Dallas County, Texas

Leticia Moreno, Individually and as Representative of the Estate of Juan Valenzuela, Deceased, and as Next Friend of D.V.M., vs. Dallas County Hospital District d/b/a Parkland Health and The University of Texas Southwestern Medical Center
Cause No. DC-24-21234, In the 116th District Court, Dallas County, Texas

Teondra L. Sparks v. DCHD d/b/a Parkland Health
Cause No. DC-25-03767, In the 160th District Court, Dallas County, Texas

CURRENT AS OF: 12/30/25
PRINTED: 12/31/25

Consideration and Appropriate Action Regarding Minutes 2026-01-27 Budget & Finance Committee

Minutes of the Budget & Finance Committee meeting of the Dallas County Hospital District, held Tuesday, January 27th, 2025, scheduled for 11:30 AM in the WISH 02-175 Executive Conference Room at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Ramon Miguez, PE, noted that a quorum was virtually present and staff were coordinating the Webex from WISH room 02-175. Mr. Miguez called the meeting to order at 11:30 a.m.

Mr. Miguez noted that due to the hazardous travel conditions, today's meeting is being held virtually via Webex under Government Code §551.125 as inclement weather prevents a quorum from safely gathering at the noticed location. The meeting space and notified location remains open with two-way communication and recording to ensure public access and compliance.

Board Member attendees (via Webex) included: Board Chair Marjorie Petty, JD, Byron Cryer, MD, Yasmin Simon, JD, Lisa Sutter, Vincent Hall and Elizabeth Palacios, MD.

Staff Present (via Webex and in-person) included:
Anthony Davis, Dir., Financial Operations
Brad Nitschke, Interim Chief Legal Officer
Brett Moran, Chief Health Officer
Donna Richardson, Chief Nursing Officer
Edmundo Castaneda, EVP & Chief Operating Officer
Enrique Gallegos, SVP & Assoc. COO
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Guy Toliver, Dir Inclusion-Supply Diversity
Joe Chang, Chief Medical Officer
Joe Mayer, Dir. Treasury
Joe Longo, Chief Information Security Officer
Keri Disney-Story, VP/Clinical Finance
Michelle Ng, Administrative Resident
Morgan Simmons, Governance Program Coordinator
Natalie Garza Vasquez, Administrative Resident
Saul Cordero, SVP & Chief Governance & Strategy Officer
Rick Humphrey, Chief Financial Officer
Tina Nam, Dir. Strat Source Contracts

Other Attendees:
N/A

II. Mission Statement

The Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After reviewing the agenda, the Chair noted that the board members present had zero conflicts of interest.

A. Reports Requiring Deliberation(s) or Approval(s)

A. Consideration and Appropriate Action Regarding Contracts over $200,000

In Pam Bryant's absence, Tina Nam reviewed the briefing documents for contracts over $200,000. (See Appendix A for these minutes for more specific details on each contract). Pam Bryant presented each contract based on expense, capital, revenue, and selection method (sole source and non-sole source).

The Committee asked questions and received additional information related to the consideration of contracts over $200,000.

Ramon Miguez motioned to remove contract M10 and M11 (Bio-Medical Applications of Texas Inc. and Dallas Nephrology Associates) from the approval process to discuss in executive session for further consideration.

Ramon Miguez asked for a motion to approve contracts over $200,000. Yasmin Simon motioned for approval. Byron Cryer seconded. The motion carried unanimously.

B. Update and Discussion Regarding Interventional Radiology Project Consolidation

Edmundo Castaneda updated the Board regarding three previously approved interventional radiology (IR) budgets—developed over the last three fiscal years—into one project totaling $9.3 million, without asking for additional funds. The consolidated scope is to construct/build out shell space and equip two new IR suites (Rooms 5 and 6) in the current IR area—both with latest biplane technology to improve throughput and efficiency—bringing us to six total suites now, while replacing the original four suites

over several years so we never drop below a minimum capacity of four. This scope shift reflects 12% IR volume growth over three years and the need to build for the future (the FY22 plan focused mainly on replacement and a C-arm for minor procedures).

Ramon Miguez asked for a motion to approve the consolidation project. Vincent Hall motioned for approval. Yasmin Simon seconded. The motion carried unanimously.

C. Consideration and Appropriate Action Regarding an Investment Committee Recommendation for a Committee Member Replacement

Richard Humphrey asked thee committee to consider a request to reappoint two Investment Advisory Committee members, Christina Wu and Joe Martinez, who have completed their initial 2022–2025 terms and are recommended for a second term through 2029, consistent with the board's three-term limit policy. A vacancy created by Mark Girbach's resignation prompted the committee's due diligence process, resulting in the recommendation of Amol Deshpande to complete the remainder of the 2026 term, with eligibility for future reappointment.

Ramon Miguez asked for a motion to approve the recommendation. Lisa Sutter motioned for approval. Vincent Hall seconded. The motion carried unanimously.

D. Update and Report Parkland Financial Performance Presentation

For the month of December, Parkland Health recognized a net income of $3.4M which is $4.5M lower than the budgeted net income of $7.9M and $3.5M unfavorable compared to the prior year net income of $6.9M. Parkland Health's operating margin and operating cash flow margin for the month of December are (1.8)% and 0.8%, respectively. The operating margin was unfavorable compared to budget of (0.01)% and the operating cash flow margin is unfavorable compared to budget of 2.9%. Parkland Health's operating margin is unfavorable compared to prior year operating margin of 1.4% and unfavorable to the operating cash flow margin of 4.6% from the prior year. Parkland Health's patient cash collections in December were $125.3M which is higher than budget by $3.3M and $13.5M above the prior year. Parkland Health's days cash on hand of 208.7 days for the month is an increase of 18.7 days compared to prior month of 190.0 days and compared to the prior year December of 196.3 days, an increase of 12.4 days.

I. Executive Session

Tex. Gov't Code §551.071

At 12:50 PM, the Board went into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

A. Consultation with Attorney Regarding Contract Items M10 and M11 (See Attached List of Contracts)

The Committee exited executive session at 1:00 PM

A. Follow-Up Requests

B. Closing Remarks

C. **Adjourn**

With no further business to discuss, Committee Chair Ramon Miguez, PE, adjourned the meeting at 1:00 pm.

SO RECORDED:

_____	_____
Ramon Miguez, PE	Brad Nitscke, JD
Committee Chair	Interim Secretary

Appendix A (Contracts Reviewed for Appropiate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									January 28, 2026
				Medical Products and Services					
M1	Expense	Mod # 5 Add Funding	BD Biosciences	9/26/2018-9/26/2026	$715,000	$3,336,557	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Hematology
M2	Expense	Mod # 1 Imager upgrade and contract extension	Hologic, Inc	1/29/2020-1/28/2029	$4,000,000	$6,665,112	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Hematology
M3	Expense	Mod #1 Purchase of additional Vanadis System	Revvity Health Sciences, Inc.	7/1/2022-Evergreen	$542,421	$8,939,812	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Chemistry
M4	Expense	Purchase of service agreement for additional Vanadis system	Revvity Health Sciences, Inc.	Date of last signature – 5 year	$300,003	$300,003	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Chemistry

M5	Capital	Siemens ARTIS Icono Ceiling Cardiology	Siemens Medical Solutions USA, Inc.	Last Signature – 2/10/2027	$901,997	$901,997	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M6	Expense	Endoscopic GI Supplies	STERIS Corporation	Last Signature – 3 Year	$614,500	$614,500	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Gastroenterology
M7	Expense	Mod # 7 Add Funds only - Level III Armed Guard Services	Vets Securing America, Inc	1/1/2022-6/30/2026	$1,320,000	$6,858,442	Non-Sole Source Modification	Yes	Marlin Suell /Police Department
M8	Capital and Expense	Purchase of the Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	Solventum	12/17/2025 – 5/19/2026	$729,612	$729,612	GPO Purchase	Yes	Pamela Bryant/Supply Chain
M9	Capital	Siemens Hardware Upgrades on Three MRI Systems	Siemens Medical Solutions USA, Inc.	Last Signature – 2/5/2027	$1,981,520	$1,981,520	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M10	Expense	Mod # 2 Adding Funds only - No Contract Action Needed – Outpatient Dialysis Services	Bio-Medical Applications of Texas, Inc.	12/1/2021-6/30/2026	$2,500,000	$18,036,993	Sole Source Modification	Yes	Shannan Bradley/Care Management
M11	Expense	Mod # 2 Adding Funds only - No Contract Action Needed – Outpatient Dialysis Services – Nephrology Services	Dallas Nephrology Associates	12/1/2021-6/30/2026	$500,000	$1,864,000	Sole Source Modification	Yes	Shannan Bradley/Care Management

Construction and Facilities									
C1	Expense	Approve this contract for Grounds Maintenance & Landscaping Services for COPC & Offsites	Bare Roots Landscape Design, Inc.	3/1/2026 – 2/28/2031	$1,959,292	$1,959,292	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shabretta Manning/Engineering Services
C2	Capital	Mod # 1 Big OK Paper Parking Lot Improvements.	Gilbert May, Inc. d/b/a Phillips May Corporation	4/24/2024-7/15/2026	$320,160	$4,313,463	Non-Sole Source Modification	Yes	Paul Woodard/Parkland Design and Construction
C3	Expense: Court Approval	Mod # 3 Amendment to Lease Agreement – DHA Lakewest Clinic	Housing Authority of Dallas	1/2/2017-1/1/2031	$254,794	$742,554	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Beall Carothers/Planning Design & Construction
C4	Capital	Garland Health Center Elevator Modernization	ThyssenKrupp Elevator	1/29/2026 – 9/28/2026	$220,897	$220,897	Sole Source	Yes	Shabretta Manning/Engineering Services
Information Technology									
IT1	Expense	Interim Director of Data Management and Enterprise Analytics	Prominence Advisors, LLC	2/2/2026 – 9/30/2026	$364,640	$364,640	Sole Source	No	James Gaston/Information Technology
IT2	Expense	Revuud - IT Consultants	Revuud, Inc.	2/17/2026 – 9/30/2026	$1,234,861	$1,234,861	Contract Award without Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	LeMar Oleson James Gaston Adam Taufique Deborah Johnson Cynthia Hamilton Mia Smith/Information Technology
IT3	Expense	Infor Streaming Pipelines and Velocity Suite	Infor	Last signature – Three years	$1,130,250	$1,130,250	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Deborah Johnson / LeMar Oleson/Information Technology

Consideration and Appropriate Action Regarding Minutes 2026-01-27 Quality of Care & Patient Safety Committee

Minutes of the Quality of Care and Patient Safety Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, January 28th, 2026, scheduled for 10:00 a.m. in the WISH building Executive Conference Room 02-175 at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Elizabeth Palacios, MD, noted that a quorum was physically present and called the meeting to order at 10:00 a.m. Committee members and Farida Minner, RN, and Byron Cryer, MD, and Todd Furniss, JD attended in person.

Board Member attendees included: Marjorie Petty, JD, Ramon Miguez, PE, Yasmin Simon, JD, and Vincent Hall.

Staff Present (via Webex and in-person) included:
Brad Nitschke, Interim EVP Legal Affairs
Brett Moran, Chief Health Officer
Carmen Bowling, SVP Nursing
David Alexander, SVP Nursing
Dawn Marchetto, SVP Nursing
Donna Richardson, EVP & Chief Nursing Officer
Edmundo Castañeda, EVP & Chief Operating Officer
Fred Cerise, President & CEO
Gretchen Blake, VP Quality & Clinical Effectiveness
James Griffin, President of the Medical Executive Committee
Judy Herrington, SVP Nursing
Karen Garvey, VP Safety & Clinical Risk Management
Kareem AbdelFattah, VP & ACMO
Kathleen Doherty, VP Nursing Surgical Services
Maggie Palmer, VP/Medical Staff Professional Services (via Webex)
Michael Lane, SVP & Chief Quality and Safety Officer
Michelle Ng, Administrative Resident
Morgan Simmons, Governance Program Coordinator
Natalie Garza Vasquez, Administrative Resident
Saul Cordero, SVP & Chief Governance & Strategy Officer
Sobha Fuller, SVP Nursing
Ryan Mauck, MD – Service Chief, Urology; Pres-Elect – Med Staff

Attendees via Webex:
Sonya Manibusan, CCP, LSSYB - Senior Director, Volunteer and Guest Services
Fadwa Ali, MD – Service Chief, Colorectal Surgery
Catherine Chen, MD, MSHI – Critical Care Service Line Chief
Joe B. Lockridge, MD, FAST - Medical Director, Kidney Transplant Program

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Executive Session – Quality & Patient Safety Operations Section

At 10:01 a.m. the Committee moved into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

In executive session, the Committee received the presentation and reports as specified in the posted agenda.

Executive Session: Quality & Patient Safety Operations (QSO)
Tex. Health & Safety Code §§161.032 & 161.0315 and Tex. Occupations. Code §160.007

A. **Update and Report by Chief Quality and Safety Officer**
Includes briefing from Executive Quality Committee (EQC)

B. **Review of Safety Event Cause Analysis (CA) Case(s)**
Shared learnings from recent safety event(s) with associated guide

C. **Update and Report Regarding Quality-Related Key Performance Indicators (KPIs)**
Reports for quality improvement project(s) throughout the enterprise

1. Department Performance Improvement Committee (PIC)/ Clinical Quality Committee (CQC) Annual Presentation(s)
Annual report from service lines related to quality and safety

   a. Medicine Services

   b. Transplant Services

D. **Update and Report Regarding Regulatory and Accreditation Affairs**
Quarterly report for Regulatory activities, tracers, and auditing

Possible Deliberation Regarding the Following

A. Executive Summaries
Overview of QSO departmental reports

B. Clinical Excellence Operating Review Update for Hospital and Population Health
Monthly update of quality key performance indicators (KPIs) for Inpatient Care and Population Health

C. Update and Report Regarding Patient Relations: Complaints, Grievances and Successes
Biannual report on Activities and trends reported through Safety Center

D. Update and Report Regarding Regulatory & Accreditation Affairs Surveys and Complaints
Quarterly update on various surveys and complaints

E. Supplemental Cause Analysis Case

F. Cause Analysis (CA) Log
List of upcoming cause analysis case reviews

VI. Executive Session: Medical Executive Committee ("MEC")

Ryan Mauck, MD, President of the Medical Executive Committee, discussed the items posted on the agenda starting at 11:25 am.

1. Medical Staff and Non-Physician Clinical Providers to Parkland Health
    a. Credentialing Report
    b. Delineation of Privileges (DoPs)
        i. Radiology DoP – Addendum
        ii. Non-Physician Clinical Provider Staff DoP – Medicine (Triage)
        iii. Non-Physician Clinical Provider Staff DoP – Women's Health (Triage)
        iv. Geriatric Medicine DoP (Full Review)
        v. Hematology and Medical Oncology DoP (Full Review)
        vi. Pulmonary Medicine DoP (Full Review)
        vii. Rheumatology DoP (Full Review)

VII. Executive Session: Discussion regarding report and/or information provided by the Chief Quality Safety Officer and related items on this agenda.

The Committee conducted a discussion with the Chief Quality & Safety Officer, SVP, Michael Lane, without other members of management present.

VIII. Executive Session: Discussion regarding report and/or information provided by the Medical Executive Committee President and related items on this agenda.

The Committee conducted a discussion with the Medical Executive Committee President, Dr. Ryan Mauck without other members of management present.

Chair adjourned Executive Session and moved into Open Session at 12:17 pm.

IX. Action Items (Open Session)

A. Consideration and Appropriate Action Regarding MEC Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

1. Credentialing Report
2. Delineation of Privileges (DoPs)
    a. Radiology DoP – Addendum
    b. Non-Physician Clinical Provider Staff DoP – Medicine (Triage)
    c. Non-Physician Clinical Provider Staff DoP – Women's Health (Triage)
    d. Geriatric Medicine DoP (Full Review)
    e. Hematology and Medical Oncology DoP (Full Review)
    f. Pulmonary Medicine DoP (Full Review)
    g. Rheumatology DoP (Full Review)

Byron Cryer motioned to approve the Medical Executive Committee Recommendations, Credentialing Report, and Delineation of Privileges. Ramon Miguez seconded the motion. The motion passed unanimously.

X. Follow-Up Requests: None

XI. Closing Remarks

XII. Adjourn

With no further business to discuss, Committee Chair Elizabeth Palacios, MD, adjourned the meeting at 12:17 pm.

SO RECORDED:

Byron Cryer, MD Committee Chair	Brad Nitschke, JD Assistant Secretary

Consideration and Appropriate Action Regarding Minutes 2026-01-27 Board of Managers

Minutes of the Board of Managers meeting of the Dallas County Hospital District, held Wednesday, January 28th, 2026, scheduled for 12:50 PM (or immediately following the HOMES meeting) in the WISH 02-175 Executive Conference Room at Parkland Health and via Webex. These minutes do not constitute a certified agenda for the meeting.

I. Attendance and Call to Order

Chair Marjorie Petty noted that a quorum was physically present and called the meeting to order at 12:50 PM.

Board Member attendees included: Vincent Hall, Lisa Sutter, Todd Furniss, JD, Farida Minner, RN, Byron Cryer, MD, Ramon Miguez, PE, Eric G. Bing, PhD, MD, Elizabeth Palacios, MD, and Yasmin Simon, JD.

Staff Present (via Webex and in-person) included:

Amy LaBarge, Chief Audit Officer
Blanca Garcia, Mgr., Strategy
Brett Moran, Chief Health Officer
Brad Nitschke, Interim Chief Legal Officer
Bruce McDaniels, VP & Chief Information Security Officer
Donna Richardson, EVP & Chief Nursing Officer
Edmundo Castañeda, EVP & Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Forrest Stovall, Program Manager Strategy
Jared Ginter, VP Inst. Risk Management
Jessica Hernandez, SVP & Chief Health Equity Officer
Joseph Chang, Chief Medical Officer
Joe Mayer, Director/Treasury
Kareem AbdelFattah, Assoc. Chief Medical Director
Keri Disney-Story, VP/Clinical Finance
Michelle Ng, Administrative Resident
Michael Lane, SVP & Chief Quality and Safety Officer
Melanie Roberts, SVP/Chief Compliance and Ethics Officer
Michael Malaise, SVP Communications/Ext. Affairs
Morgan Simmons, Governance Program Manager
Natalie Garza Vasquez, Administrative Resident
Richard Humphrey, EVP & CFO
Samia Zia, Dir., Strategy
Saul Cordero, SVP & Chief Governance & Strategy Officer

Additional Attendees:
Idalia Amaya
Nate Weinstein – Osmosis

Ryan Bailey – Chair of the Investment Committee
Kristen Harrison – Smith Group

II. Mission Statement

The Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Invocation

Rev. Sandra Cabrera offered an invocation at the beginning of the meeting.

IV. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

V. Public Comments Regarding Non-Agenda Items

No members of the public registered for comments regarding non-agenda items.

VI. Conflicts of Interest

After reviewing the agenda, the Chair noted there were no conflicts of interest on the agenda.

VII. Consent Agenda

I. Consent Agenda: Minutes

A. Consideration and Appropriate Action Regarding Minutes 2025-12-16 Budget & Finance Committee

B. Consideration and Appropriate Action Regarding Minutes 2025-12-17 Quality of Care & Patient Safety Committee

C. Consideration and Appropriate Action Regarding Minutes 2025-12-17 Board of Managers

II. Consent Agenda: Contracts

A. Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**

III. Consent Agenda: Policies

A. Consideration and Appropriate Action Regarding Sys.Lead.008 Managing Conflict Among Leadership Groups Policy Triennial Review

IV. Consent Agenda: Other

A. Consideration and Appropriate Action Regarding Three Grants from the Office of the Governor and Public Safety Regarding Criminal Justice Programs, General Victim Assistance and Residential Substance Abuse

B. Consideration and Appropriate Action Regarding 2026 Southwestern Medical District Budget

C. Consideration and Appropriate Action Regarding Resolution for AR Financing and Change in Management for Parkland Avir Nursing Homes

D. Consideration and Appropriate Action Regarding General Counsel Interim Authority Resolution

V. Consent Agenda: Medical Executive Committee Items

A. Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

Marjorie Petty asked if any items need to be pulled from the consent agenda for further discussion. None were removed.

Marjorie asked for a motion to approve the consent agenda. Lisa Sutter motioned for approval of the consent agenda. Todd Furniss seconded. The motion carried unanimously.

VI. Reports Requiring Deliberation(s) or Approval(s)

A. CEO Update on System Operations and Board FY26Q1 Priorities Discussion
Dr. Cerise reported that Parkland is advancing its FY26 Board priorities across Productivity, Access, Quality, Trust, People, and Facilities. FTE per AOB productivity is ahead of target, and Finance Index measures show mixed progress requiring continued focus. Access improvements include significant reductions in appointment wait times and ongoing work toward Digital Health goals. Quality initiatives in the hospital and ambulatory settings remain central, with several outcome metrics tracking toward targets. Patient Experience and Engagement indicators are stable as the One Survey progresses. Succession planning for key executive roles is underway, and major facility projects are moving into design and procurement phases.

B. Consideration and Appropriate Action Regarding - Investment Committee Report and Recommendation – Private Markets Investment Manager
The investment committee chair, Ryan Bailey, and Joe Mayer presented to the Board regarding the private markets investment manager. The committee selected GCM for its strong track record, customized approach, and senior-level engagement. GCM also offers smoother transition support than other firms, which the board viewed as a major advantage. The recommendation is to commit roughly $100–110 million per manager, aligned with existing policy. Performance will be monitored through regular quarterly reports and oversight from the investment advisory committee, with the board retaining final decision-making authority. Private equity and private debt carry higher risk but offer

stronger long-term return potential and reflect broader market trends toward private financing over traditional banking.

Break

VII. Executive Session

At 1:50 PM, the Board went into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

A. Discussion Regarding Potential New Service Lines and Property Acquisition *Tex. Gov't Code §551.072, §551.085*
B. Discussion Regarding Enterprise Risk Management *Texas Occupational Code §418.183*
C. Consultation with Attorney Regarding Qui Tam *Tex. Gov't Code 551.071*
D. Consultation with Attorney Regarding Attorney General Paxton Memo *Tex. Gov't Code 551.071*
E. Consultation with Attorney Regarding Pending Litigation (*Dallas County Hospital District v. BARA, et al*) *Tex. Gov't Code 551.071*
F. Update and Report Regarding Parkland's Cybersecurity Ongoing Initiatives *Tex. Gov't Code §551.089*

Chair adjourned Executive Session and moved into Open Session at 4:08 PM.

VII. Reports Requiring Deliberation(s) and/or Possible Action Cont.

A. Board Self-Assessment
Taylor Carlson from the Governance Institute presented this year's findings which show strong effectiveness, engagement, and alignment with national benchmarks, with notable gains over prior years. Taylor reviewed the assessment structure, explaining top-box scoring and the use of both Likert and 0–10 scales to highlight areas of strength and opportunity. Parkland's board exceeded its previous year's scores and outperformed national benchmarks on overall effectiveness, board experience, and influence on strategy, culture, and performance—reflecting strong alignment and engagement. Taylor recommended that the board identify two to three

high-level governance goals, assign owners, and establish timelines to ensure measurable progress at the annual Board planning session in April.

B. Discussion Regarding Board Elections

Marjorie Petty discussed with the Board how this year's elections will take place. A verbal voting system (by show of hands) occurred as Marjorie read out loud the candidates for each position. The position of Board Chair and Secretary were unopposed positions. Marjorie asked the Board to vote on these two positions as a slate with Vincent Hall for Chair of the Board and Farida Minner as the secretary.

Marjorie asked for a motion to approve the slate. Ramon Miguez motioned. Todd Furniss seconded. The slated positions for Board Chair and Secretary passed unanimously.

Next, Marjorie allowed the candidates for the Vice Chair position to speak for 3 minutes regarding their intent for the position. Todd Furniss began followed by Yasmin Simon. After both candidates were finished, a verbal vote (by show of hands) was taken.

Marjorie asked for all in favor of Todd Furniss as Vice Chair – Farida Minner, Todd Furniss, and Elizabeth Palacios raised their hands.

Marjorie asked for all in favor of Yasmin Simon as Vice Chair – Eric Bing, Lisa Sutter, Marjorie Petty, Byron Cyrer, Ramon Miguez, Vincent Hall and Yasmin Simon voted for Yasmin Simon as Vice Chair.

Marjorie announced Yasmin Simon as Vice Chair.

VIII. Action Items

A. Board May Take Action on Any Agenda Item(s) Above

IX. Adjourn

With no further business to discuss, the Chair adjourned the meeting at 4:54 PM.

SO RECORDED:

Vincent Hall	Brad Nitschke, JD
Chair	Assistant Secretary

Appendix A (Contracts Reviewed for Appropriate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									January 28, 2026
				Medical Products and Services					
M1	Expense	Mod # 5 Add Funding	BD Biosciences	9/26/2018-9/26/2026	$715,000	$3,336,557	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Hematology
M2	Expense	Mod # 1 Imager upgrade and contract extension	Hologic, Inc	1/29/2020-1/28/2029	$4,000,000	$6,665,112	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Hematology
M3	Expense	Mod #1 Purchase of additional Vanadis System	Revvity Health Sciences, Inc.	7/1/2022-Evergreen	$542,421	$8,939,812	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Chemistry
M4	Expense	Purchase of service agreement for additional Vanadis system	Revvity Health Sciences, Inc.	Date of last signature – 5 year	$300.003	$300.003	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Chemistry
M5	Capital	Siemens ARTIS Icono Ceiling Cardiology	Siemens Medical Solutions USA, Inc.	Last Signature – 2/10/2027	$901,997	$901,997	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M6	Expense	Endoscopic GI Supplies	STERIS Corporation	Last Signature – 3 Year	$614,500	$614,500	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Gastroenterology
M7	Expense	Mod # 7 Add Funds only - Level III Armed Guard Services	Vets Securing America, Inc	1/1/2022-6/30/2026	$1,320,000	$6,858,442	Non-Sole Source Modification	Yes	Marlin Suell /Police Department
M8	Capital and Expense	Purchase of the Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	Solventum	12/17/2025 – 5/19/2026	$729,612	$729,612	GPO Purchase	Yes	Pamela Bryant/Supply Chain

M9	Capital	Siemens Hardware Upgrades on Three MRI Systems	Siemens Medical Solutions USA, Inc.	Last Signature – 2/5/2027	$1,981,520	$1,981,520	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M10	Expense	Mod # 2 Adding Funds only - No Contract Action Needed – Outpatient Dialysis Services	Bio-Medical Applications of Texas, Inc.	12/1/2021-6/30/2026	$2,500,000	$18,036,993	Sole Source Modification	Yes	Shannan Bradley/Care Management
M11	Expense	Mod # 2 Adding Funds only - No Contract Action Needed – Outpatient Dialysis Services – Nephrology Services	Dallas Nephrology Associates	12/1/2021-6/30/2026	$500,000	$1,864,000	Sole Source Modification	Yes	Shannan Bradley/Care Management
				Construction and Facilities					
C1	Expense	Approve this contract for Grounds Maintenance & Landscaping Services for COPC & Offsites	Bare Roots Landscape Design, Inc.	3/1/2026 – 2/28/2031	$1,959,292	$1,959,292	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shabretta Manning/Engineering Services
C2	Capital	Mod # 1 Big OK Paper Parking Lot Improvements.	Gilbert May, Inc. d/b/a Phillips May Corporation	4/24/2024-7/15/2026	$320,160	$4,313,463	Non-Sole Source Modification	Yes	Paul Woodard/Parkland Design and Construction
C3	Expense: Court Approval	Mod # 3 Amendment to Lease Agreement – DHA Lakewest Clinic	Housing Authority of Dallas	1/2/2017-1/1/2031	$254,794	$742,554	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Beall Carothers/Planning Design & Construction
C4	Capital	Garland Health Center Elevator Modernization	ThyssenKrupp Elevator	1/29/2026 – 9/28/2026	$220,897	$220,897	Sole Source	Yes	Shabretta Manning/Engineering Services
				Information Technology					
IT1	Expense	Interim Director of Data Management and Enterprise Analytics	Prominence Advisors, LLC	2/2/2026 – 9/30/2026	$364,640	$364,640	Sole Source	No	James Gaston/Information Technology
IT2	Expense	Revuud - IT Consultants	Revuud, Inc.	2/17/2026 – 9/30/2026	$1,234,861	$1,234,861	Contract Award without Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	LeMar Oleson James Gaston Adam Taufique Deborah Johnson Cynthia Hamilton Mia Smith/Information Technology
IT3	Expense	Infor Streaming Pipelines and Velocity Suite	Infor	Last signature – Three years	$1,130,250	$1,130,250	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Deborah Johnson / LeMar Oleson/Information Technology

Consideration and Appropriate Action Regarding Minutes 2026-01-30 Talent Development and Executive Compensation Committee

Minutes of the Talent Development and Executive Compensation Committee meeting of the Board of Managers of the Dallas County Hospital District held Friday, January 30th , 2026, scheduled for 12:30 p.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via Webex. These minutes do not constitute a certified agenda for the meeting.

I. Attendance and Call to Order

Committee Chair Lisa Sutter noted a quorum was physically present and called the meeting to order at 11:09 a.m. Committee members Farida Minner, RN, Vincent Hall, and Elizabeth Palacios, MD, were present.

Board Member attendees included: Marjorie Petty, JD, Yasmin Simon, JD, and Ramon Miguez, PE.

Staff Present (via Webex and in-person) included:

Brad Nitschke, Interim Chief Legal Officer
Dan Enright, Director/Talent Mgmt. Analytics
DeLancey Johnson, SVP & Associate Chief Talent Officer
Donna Richardson, Chief Nursing Officer
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Jessica Hernandez, SVP & Chief Health Equity Officer
Michelle Ng, Administrative Resident
Melanie Roberts, SVP Chief Compliance and Ethics Officer
Morgan Simmons, Governance Program Coordinator
Natalie Garza Vasquez, Administrative Resident
Saul Cordero, SVP & Chief Governance & Strategy Officer
Shauntee Mayfield, VP Chief Experience Officer
Sean Gorman, Mgr., Communications
Stacy Dorsey, SVP Workforce Strategy
Stephanie Speights, SVP/Talent Mgmt Development
Rick Humphrey, EVP & CFO
Torey Johnson, Sr. Dir., Learning and Leading Dev.

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Office of Talent Management Overview of Department Level Goals and Commitment

Felicia Miller reminded the Board of Parkland's commitment to be the employer of choice for those with a calling to serve through transformational experience. The Office of Talent Management upholds this commitment through recruitment, development, rewards and engagement.

B. Workday: Go-Live Updates

Dr. DeLancey Johnson and Stacy Dorsey provided an update on the Workday implementation, Parkland's new human capital management system that was launched in early January. Dr. Johnson noted a successful transition from PeopleSoft and strong engagement with over 12,000 employees logged in and the majority completing training. Ticket volumes remain manageable, with over 1,000 resolved and key trends identified in payroll, direct deposit, and mobile app notifications. The team focuses on stabilization, standardization, and optimization efforts, ensuring integrations function correctly and payroll remains accurate. Change management emphasized transparent communication, rounding, and rapid issue resolution. Priorities include minimizing disruption, addressing defects, and supporting employees' ability to perform their work effectively.

C. Benefits Update: Progress and Recent Work

Dr. Johnson provided an update on ongoing initiatives to move from a reactive to a proactive benefits strategy. A new annual roadmap outlines goals across access, plan design, and long-term strategic planning, including risk stratification and exploration of future network and plan options. Weight-management services were expanded at the Employee Health Center to support GLP-1 management, and tobacco-cessation resources accompany new surcharge policies. Recent negotiations with Cigna secured a three-year commitment without disruption. KPI review highlighted rising high-cost claims and pharmacy spend, prompting predictive modeling and closer oversight. Overall plan performance remains stable with defined reserves and ongoing monitoring.

D. Executive Succession Planning 2026 Implementation Timeline, Guiding Principles, and Soliciting Input on Executive Profiles

Stephanie Speights outlined the structured approach for Parkland's CEO and senior-leader succession planning. She emphasized a three-stage process: developing success profiles, conducting interviews and discussions, and calibrating results through

standardized templates. Current workforce data—including age, tenure, and retirement indicators—will inform risk assessment and planning. The 2026 priority is completing profiles for key chief-level roles, supported by a four-month project timeline. Stephanie highlighted the need for leadership-development alignment, noting existing skill-building programs. The session concluded with confirmation that agenda and materials were developed in coordination with the Chief Governance Officer and committee chair.

VI. Executive Session

At 11:41 a.m., the Committee went into executive session to discuss the items on the Executive Session agenda.

Members of management were excused from the discussion of topics as necessary. Only Dr. Fred Cerise and Felicia Miller remained present in the room.

A. Discussion Regarding Executive Succession Plan ***Tex. Government Code §§551.074***

Lisa Sutter, adjourned Executive Session and moved into Open Session at 12:24 p.m.

VII. Adjourn

With no further business to discuss, Lisa Sutter adjourned the meeting at 12:25 p.m.

SO RECORDED:

_____	_____
	Brad Nitschke, JD
Committee Chair	Assistant Secretary

Consideration and Appropriate Action Regarding Contracts over $200,000

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									February 25, 2026
Medical Products and Services									
M1	Expense	Mod # 1 Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents	Becton and Dickinson and Company	3/20/2023 - 3/19/2028	$85,000	$201,000	Sole Source Modification	Yes	Scott Hampton/Tim Lenz/Laboratory Services - Microbiology
M2	Expense	Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems	Biomet Microfixation, LLC	2/25/2026 – 2/24/2029	$850,000	$850,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan/Periop Services
M3	Expense	Coronary Stents and Accessories	Boston Scientific	3/1/2026 – 2/28/2031	$2,250,000	$2,250,000	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Cardiac Cath Lab
M4	Expense	EchoTip Insight Portosystemic Pressure Gradient Measuring System	Cook Medical, Inc	2/25/2026 – 2/26/2031	$350,000	$350,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan/Periop Services
M5	Expense	Mod # 1 Adding Additional Funding for Genetic Testing Services through Exact Sciences	Exact Sciences Laboratories, LLC	1/29/2024 - 2/28/2027	$170,000	$420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services - Microbiology
M6	Expense	Mod # 1 Add Funding for Genetic Testing through Foundation Medicine Inc.	Foundation Medicine Inc.	3/28/2024 - 4/30/2026	$150,000	$500,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Scott Hampton/Tim Lenz/Laboratory Services

M7	Capital	Cardiac Stress Systems	GE Healthcare	3/6/2026 – 3/5/2027	$222,824	$222,824	GPO Purchase	Yes	Patrick Eaton/Clinical Engineering
M8	Expense	Mod # 3 Neurosurgical Implants	Integra LifeSciences	1/1/2021-12/31/2027	$1,401,000	$4,420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Surgical Services Administration
M9	Expense	Mod # 1 One Year Contract Extension for OCD Diana Reagents	Polymedco Cancer Diagnostic Products, LLC	3/1/2023-2/28/2027	$270,000	$874,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tim Lenz/Laboratory Services - Pathology
M10	Expense	Mod # 1 Neurovascular Implants	Stryker Neurovascular	1/1/2019-12/31/2026	$361,000	$2,646,100	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M11	Expense	Mod # 5 Biotel Emergency Medical Services	The University of Texas Southwestern Medical Center	10/16/2016-9/30/2026	$134,480	$583,714	Contract Extension without Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Melody Gardner and Courtney Edwards/Biotel Department
M12	Expense	Mod # 1 On-Call Coverage for Patient Safety Officer and Clinical Post Transplant Coordinator Services	Transplant Coordinators of America	7/1/2021-6/30/2026	$219,000	$919,000	Sole Source Modification	Yes	Linda Kautzman
M13	Expense	Signatera Genetic Test	Natera	2/27/2026 – 2/26/2029	$537,000	$537,000	Sole Source	Yes	Scott Hampton/Tim Lenz/Laboratory Services – Referral Lab

M14	Expense	Mod # 1 Request Additional Funds for Blood and Blood Products	BloodSolutions, LLC dba Bloodbuy	3/7/2022-Evergreen	$250,000	$446,000	Sole Source Modification	Yes	Tim Lenz/Amy Sigman/Laboratory Services - Transfusion Services
M15	Capital and Expense	Alaris Pump Modules, and associated software	BD CareFusion	2/25/2026 –1/31/2028	$843,880	$843,880	GPO Purchase	Yes	Patrick Eaton/ Clinical Engineering
Construction and Facilities									
C1	Capital	Central Utility Plant (CUP) Boiler Burner Replacement	Burner Combustion Systems LLC	2/26/2026 – 8/25/2026	$414,030	$414,030	Invitation for Bids	Yes	David Alvarez/Engineering Services
C2	Revenue: Court Approval	Eleventh Amendment to Lease Agreement	The Board of Regents of the University of Texas System for the use and benefit of the University of Texas Southwestern Medical Center at Dallas	4/1/2008-3/31/2031	$126,737	$1,233,067	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Beall Carothers/Planning Design & Construction
Information Technology									
IT1	Expense	Bryte Assistive AI SaaS for UKG Pro WFM	UKG Kronos Systems LLC	3/1/2026 – 2/28/2029	$867,000	$867,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Deborah Johnson/Information Technology
Hospital Operations									
O1	Expense	Mod # 1 Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) – External Audit	Health Information Associates	5/1/2025-4/30/2028	$80,000	$2,570,440	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Mandy Transou/HIM Coding Integrity

O2	Expense	Mod # 1 Consulting Services for Affordable Care Act (ACA) Exchange	Milliman, Inc.	11/1/2024-11/31/2026	$1,600,000	$2,890,000	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristin Alvarez/Value Based Care
Ratification/Deviation/Informational Only									
D1	Expense-Approved Deviation	Consulting Services for Children's Health Impact Assessment & Improvement Actions, and Parkland Health Plan Contribution Margin Improvement.	Shara McClure Health Solutions	2/13/2026 – 8/12/2026	$650,000	$650,000	Sole Source	Yes	Edmundo Castaneda/Administration

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents	
Business Owner: Scott Hampton/Tim Lenz	**Business Owner Dept:** Laboratory Services - Microbiology	**Contract Number:** POCP-21943
Vendor/Supplier: Becton and Dickinson and Company **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Amount:	$116,000
	Total amount of actions since last approval	$0
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$85,000
Original Start Date: 3/20/2023 **Current Expiration:** 3/19/2026 **Mod Start Date:** 3/20/2026 **Expiration after this Mod:** 3/19/2028	New Board Approved Amount:	$201,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes
FTE Impact:	None

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents

VENDOR: Becton and Dickinson and Company

COST:		
	Current Amount:	$116,000
	Actions since last approval	$0
	Board amount requested # 1:	+ $85,000
	Total:	$201,000

Recommendation
Approve this contract modification for Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents.

Background
This contract provides testing material and consumables for Acid-Fast Bacillus (AFB) testing in Microbiology on the Parkland-owned BACTEC MGIT instrument. AFB testing is a medical test used to detect acid-fast bacteria, the bacteria that cause tuberculosis (TB). No other vendor can supply this product for testing on this instrument.

Fair and Reasonable Price Determination

Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that Parkland's pricing is aligned with the 25th percentile and remains lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
$116,000	$49,583	$35,417	$201,000

Sole Source Justification
The compatibility of equipment, accessories, or replacement parts is the paramount consideration, and there is no assurance that other suppliers will perform the same function, including additions or modifications to existing systems, software, licenses, maintenance, etc. Parkland owns this testing equipment.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems	
Business Owner: Cheston Chan	**Business Owner Dept:** Periop Services	**Contract Number:** POCP-25949
Vendor/Supplier/Contractor: Biomet Microfixation, LLC	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	2/25/2026 – 2/24/2029	$510,000
Out Years:	2 Year(s)	+$340,000
Total:	2/25/2026 – 2/24/2029	$850,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder?

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems

VENDOR: Biomet Microfixation, LLC

COST:		
	Base Term:	$510,000
	Out Years:	+ $340,000
	Total:	$850,000

Recommendation
Approve this contract for Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems.

Background
This contract is for Craniomaxillofacial (CMF) and Thoracic Fixation Systems, including bone plates, screws, and implants. These items are used in the operating room during reconstruction and dental procedures to stabilize and repair bones.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 1% higher than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables	$113,333	$170,000	$170,000	$56,667			$510,000
Out Years	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables				$113,333	$170,000	$56,667	$340,000
Grand Totals	$113,333	$170,000	$170,000	$170,000	$170,000	$56,667	$850,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Andrea Henley

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Coronary Stents and Accessories	
Business Owner: David Alexander	**Business Owner Dept:** Cardiac Cath Lab	**Contract Number:** POCP-25527
Vendor/Supplier/Contractor: Boston Scientific	**Source Selection Methodology:** Request for Proposals (Best Value)	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense, or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	3/1/2026 – 2/28/2029	$1,350,000
Out Years:	2 Year(s)	+$900,000
Total:	3/1/2026 – 2/28/2031	$2,250,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? Yes

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Coronary Stents and Accessories

VENDOR: Boston Scientific

COST:

Base Term:	$1,350,000
Out Years:	+ $900,000
Total:	$2,250,000

Recommendation
Approve this contract for Coronary Stents and Accessories.

Background
This contract is for Coronary Stents and Accessories and was solicited through an RFP that resulted in a dual-vendor award. One vendor of the dual award has been awarded and approved by the state the board meeting, and this contract represents the award to the second vendor. The stents are used to treat heart artery blockages, and the accessories assist in their placement during procedures in the Cardiac Catheterization Lab.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition. Boston Scientific scored slightly lower than the highest technically rated offeror. It was determined that the higher technical score of Vendor C did not justify the higher price.

Competitive Range				
Vendor	**Key Strengths**	**Key Weaknesses**	**Non-Cost Score**	**Price Differential**
Vendor A	Adoption of Vendor A coronary has been very positive, and users are very pleased with our process and outcome.		124	$0
Boston Scientific	Boston Scientific provides sole source products surgeons need, and Boston Scientific provides the highest savings of the bids received.		143	$0
Vendor C		Awarding Vendor C would require a conversion that would result in soft costs to the Cardiac Catheterization Lab not reflected in the Price Differential.	144	$14,717

Financial Forecast

Base Term	FY2026	FY2027	FY2028	FY2029	FY2030	FY2031	Totals
Expenses / Consumables	$300,000	$450,000	$450,000	$150,000			$1,350,000
Out Years	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables				$300,000	$450,000	$150,000	$900,000
Grand Totals	**$300,000**	**$450,000**	**$450,000**	**$450,000**	**$450,000**	**$150,000**	**$2,250,000**

Document Contact/Author:	Bryson Hendrix

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** EchoTip Insight Portosystemic Pressure Gradient Measuring System	
Business Owner: Cheston Chan	**Business Owner Dept:** Periop Services	**Contract Number:** POCP-25834
Vendor/Supplier/Contractor: Cook Medical, Inc.	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	2/25/2026 – 2/26/2029	$210,000
Out Years:	2 Year(s)	+$140,000
Total:	2/25/2026 – 2/26/2031	$350,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: EchoTip Insight Portosystemic Pressure Gradient Measuring System

VENDOR: Cook Medical, Inc.

COST:		
	Base Term:	$210,000
	Out Years:	+ $140,000
	Total:	$350,000

Recommendation
Approve this contract for EchoTip Insight Portosystemic Pressure Gradient Measuring System.

Background
This contract is for the EchoTip Insight Portosystemic Pressure Gradient Measuring System, for use in the Gastrointestinal (GI) Lab to directly measure portal and hepatic venous pressures under Endoscopic Ultrasound (EUS) guidance.

Patients are sent to Interventional Radiology and typically catheterized through the neck or groin to capture measurements of the hepatic and portal vein to determine the severity of liver disease. This system would allow consolidation of multiple procedures into a single procedure when coupled with routine endoscopic exams, biopsies, and EUS procedures.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is the average price paid by other member hospitals of equal or similar size. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables	$46,667	$70,000	$70,000	$23,333			$210,000
Out Years	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables				$46,667	$70,000	$23,333	$140,000
Grand Totals	**$46,667**	**$70,000**	**$70,000**	**$70,000**	**$70,000**	**$23,333**	**$350,000**

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. This is the only system on the market that allows for the measurement of portal and hepatic pressures during endoscopy. The product or service has no competition.

Document Contact/Author:	Andrea Henley

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod #1 Adding Additional Funding for Genetic Testing Services through Exact Sciences	
Business Owner: Scott Hampton/Tim Lenz	**Business Owner Dept:** Laboratory Services	**Contract Number:** PO 9900
Vendor/Supplier: Exact Sciences Laboratories, LLC **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Previous Board Approved Amount:	$250,000
	Total amount of actions since last approval	$0
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$170,000
Original Start Date: 1/29/2024 **Last BOM Approval Date:** 03/27/2024 **Current Expiration:** 2/28/2026 **Mod Start Date:** 3/1/2026 **Expiration after this Mod:** 2/28/2027	New Board Approved Amount:	$420,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Material terms approved by Legal
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 Adding Additional Funding for Genetic Testing Services through Exact Sciences

VENDOR: Exact Sciences Laboratories, LLC

COST:	Previous Board Approved Amount:	$250,000
	Actions since last approval	$0
	Board amount requested # 1:	+ $170,000
	Total:	$420,000

Recommendation
Approve this contract modification Adding Additional Funding for Genetic Testing Services through Exact Sciences.

Background
This contract covers the purchase of specialized genetic testing services. Exact Sciences provides a proprietary genomic assay used by the Pathology department to assess breast cancer recurrence risk. The agreement is renewed annually to allow for funding oversight and expense tracking while the contract is being finalized. A yearly PO will be required until the contract is complete.

Fair and Reasonable Price Determination

Pricing is established by law or regulation and has remained unchanged since Parkland began using these testing services three years ago.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
$250,000	$99,167	$70,833	$420,000

Sole Source Justification
This contract is for a service for which there is only one acceptable source. The product or service has no competition.

Document Contact/Author:	Tamisha Smallwood

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Add Funding for Genetic Testing through Foundation Medicine Inc.	
Business Owner: Scott Hampton/Tim Lenz	**Business Owner Dept:** Laboratory Services	**Contract Number:** PO 10213
Vendor/Supplier: Foundation Medicine Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Previous Board Approved Amount:	$350,000
	Total amount of actions since last approval	$0
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$150,000
Original Start Date: 3/28/2024 **Last BOM Approval Date:** 3/27/2024 **Current Expiration:** 3/27/2026 **Mod Start Date:** 2/26/2026 **Expiration after this Mod:** 4/30/2026	New Board Approved Amount:	$500,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Material terms approved by Legal
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 Add Funding for Genetic Testing through Foundation Medicine Inc.

VENDOR: Foundation Medicine Inc.

COST:

Previous Board Approved Amount:	$350,000
Actions since last approval	$0
Board amount requested # 1:	+ $150,000
Total:	$500,000

Recommendation
Approve this contract modification to Add Funding for Genetic Testing through Foundation Medicine Inc.

Background
This contract is for genetic testing services that provide FDA-approved testing of predictive and prognostic tumor markers for the treatment of various cancers, using both blood and tissue specimens.

Fair and Reasonable Price Determination

Benchmarking research was conducted through ECRI, and they were unable to provide price recommendations; however, the vendor is extending the current historical pricing. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	Total
$350,000	$150,000	$500,000

Sole Source Justification
FoundationOne Liquid CDx is the only FDA-approved, blood-based test to analyze over 300 genes, making it the most comprehensive FDA-approved liquid biopsy on the market. This contract is for a service for which there is only one acceptable source. The product or service has no competition.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Cardiac Stress Systems	
Business Owner: Patrick Eaton	**Business Owner Dept:** Clinical Engineering	**Contract Number:** POCP-26024
Vendor/Supplier/Contractor: GE Healthcare	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	3/6/2026 – 3/5/2027	$222,824
Out Years:	0 Year(s)	+$0
Total:	3/6/2026 – 3/5/2027	$222,824

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Submitted By (Division VP): Lance Mendiola, Vice President, Construction, Facilities, Real Estate

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Cardiac Stress Systems

VENDOR: GE Healthcare

COST:		
	Base Term:	$222,824
	Out Years:	+ $0
	Total:	$222,824

Recommendation
Approve this contract for Cardiac Stress Systems.

Background

This contract is for six (6) cardiac stress systems, replacing Parkland's current inventory of six (6) systems, which range in age from 9 to 11 years old. All have reached the end of support (i.e., no longer have access to vendor support or parts to maintain the equipment). The systems reside at the main hospital and the Ron J. Anderson (RJA) clinic. They are used in noninvasive cardiology and nuclear medicine.

Fair and Reasonable Price Determination
The GPO contract and pricing were obtained in a solicitation process performed by Vizient. Market research conducted through ECRI shows that Parkland's price is average compared to other hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2026
Equipment / Licenses	$222,824

Document Contact/Author:	Andrew Barter

Item M8

Board Approval Request
For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 4 Neurosurgical Implants	
Business Owner: David Alexander	**Business Owner Dept:** Surgical Services Administration	**Contract Number:** POCP-18029 A5
Vendor/Supplier: Integra LifeSciences **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (2/22/23):	$2,920,000
	Actions Totaling < $100,000 Amount: Amount: Amount:	$99,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 4 Amount:	$1,401,000
Original Start Date: 1/1/2021 **Current Expiration:** 2/28/2026 **Mod Start Date:** 3/1/2026 **Expiration after this Mod:** 12/31/2027	New Contract Amount:	$4,420,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 4 Neurosurgical Implants

VENDOR: Integra LifeSciences

COST:

BOM Approved Contract Total (2/22/23):	$2,920,000
Action:	$99,000
Action:	
Action:	
Modification # 4:	+ $1,401,000
Total:	$4,420,000

Recommendation

Approve this contract modification to Neurosurgical Implants.

Background

This contract is for the procurement of neurosurgical implants used to repair the lining of the brain and spinal cord. These products are used for cranial reconstruction, dural repair, hydrocephalus management, nerve repair, and stabilization of the skull and spine.

Fair and Reasonable Price Determination

Although the items being purchased are a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Parklands pricing is currently 22% above ECRI average. Through negotiations in person and otherwise, the vendor has now provided their 4th offer, which results in Parkland's annual spend going from an estimated $581,026 to $523,648, yielding savings of $57,000. Market research conducted through ECRI shows that the Parkland price is 14% higher than the average for other member hospitals through this renewal. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	Total
$2,920,000	$562,500	$750,000	$187,500	$4,420,000

Sole Source Justification

This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Bryson Hendrix

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 One-Year Contract Extension for OCD Diana Reagents	
Business Owner: Tim Lenz	**Business Owner Dept:** Laboratory Services - Pathology	**Contract Number:** POCP-22139
Vendor/Supplier: Polymedco Cancer Diagnostic Products, LLC **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Previous Board Approved Amount:	$600,000
	Total amount of actions since last approval	$4,000
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$270,000
Original Start Date: 3/1/2023 **Last BOM Approval Date:** 01/25/2023 **Current Expiration:** 2/28/2026 **Mod Start Date:** 3/1/2026 **Expiration after this Mod:** 2/28/2027	New Board Approved Amount:	$874,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 One-Year Contract Extension for OCD Diana Reagents

VENDOR: Polymedco Cancer Diagnostic Products, LLC

COST:

Previous Board Approved Amount:	$600,000
Actions since last approval	$4,000
Board amount requested # 1:	+$270,000
Total:	$874,000

Recommendation
Approve this contract modification for the One-Year Contract Extension for OCD Diana Reagents.

Background
This request is for a one-year extension of the OCD Diana reagents used with Polymedco test kits for oncology testing in the Pathology Lab. We are currently in the contract's option period, which allows for two one-year renewals. These kits and reagents are exclusively manufactured by Polymedco for use with the Parkland-owned Polymedco OCD-Diana instrument.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price remains in the median price range compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027	Total
$600,000	$4,000	$157,500	$112,500	$874,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The product or service has no competition. The kits manufactured by Polymedco are proprietary to the Polymedco OCD-Diana instrumentation, which Parkland owns.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request
For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Neurovascular Implants	
Business Owner: Shawn Grady	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-18506 A11
Vendor/Supplier: Stryker Neurovascular **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (9/24/25):	$2,285,100
	Actions Totaling < $100,000 Amount:	$0
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 1 Amount:	$361,000
Original Start Date: 1/1/2019 **Current Expiration:** 12/31/2026 **Mod Start Date:** 2/25/2026 **Expiration after this Mod:** 12/31/2026	New Contract Amount:	$2,646,100

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 Neurovascular Implants

VENDOR: Stryker Neurovascular

COST:

BOM Approved Contract Total (9/24/25):	$2,285,100
Action:	$0
Action:	
Action:	
Modification # 1:	+ $361,000
Total:	$2,646,100

Recommendation

Approve this contract modification to Neurovascular Implants.

Background

This contract facilitates the procurement of neurovascular coils and related accessories used in the treatment of acute ischemic stroke. These Stryker products are specifically designed to remove intracranial blood clots and manage hemorrhagic events. Additional funding supports purchases through the end of the contract term.

Fair and Reasonable Price Determination

Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price aligns with other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
$2,285,100	$240,667	$120,333	$2,646,100

Sole Source Justification

This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc., are patient care devices and are exempt.

Document Contact/Author:	William Jones

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 5 Biotel Emergency Medical Services	
Business Owner: Melody Gardner and Courtney Edwards	**Business Owner Dept:** Biotel Department	**Contract Number:** POCS-19839 A5
Vendor/Supplier: The University of Texas Southwestern Medical Center **Basis of Original Contract Award** Interlocal agreement **Basis of this Modification** Contract Extension without Competition	Previous Board Approved Amount:	$449,234
	Total amount of actions since last approval	
Revenue, Expense or Capital: Expense	Current amount requested: # 5:	$134,480
Original Start Date: 10/16/2016 **Last BOM Approval Date:** 9/25/2024 **Current Expiration:** 9/30/2026 **Mod Start Date:** 10/1/2025 **Expiration after this Mod:** 9/30/2026	New Board Approved Amount:	$583,714

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Dawn Marchetto, SVP Nursing

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 5 Biotel Emergency Medical Services

VENDOR: The University of Texas Southwestern Medical Center

COST:

Previous Board Approved Amount:	$449,234
Actions since last approval	
	+ $134,480
Board amount requested # 5:	
Total:	$583,714

Recommendation
Approve this contract modification to Biotel Emergency Medical Services.

Background
This contract is for Biotel subcontracted services. Parkland provides Biotel services to multiple EMS agencies. Part of those Biotel services (e.g., medical direction) is provided by the University of Texas Southwestern Medical Center. This expense is offset by the revenue Parkland receives from those EMS agencies. These Biotel services are provided by Parkland's Emergency Services Department's Biotel Team.

This modification extends the term of the underlying contract with the University of Texas Southwestern Medical Center by another year.

Fair and Reasonable Price Determination
Amounts are determined to be fair and reasonable based on historical pricing.

Financial Forecast

Current Contract Amount	FY2026	Total
$449,234	$134,480	$583,714

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. The contract is an interlocal agreement which is between local government entities or political subdivisions of the state of Texas to carry out a governmental purpose. Examples are contracts with UT, the City of Dallas, Dallas County, etc. that serve our governmental purpose of providing care to the indigent. The government entity for this contract is the University of Texas Southwestern Medical Center.

Document Contact/Author:	Stephanie Toth

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 On-Call Coverage for Patient Safety Officer and Clinical Post-Transplant Coordinator Services	
Business Owner: Linda Kautzman	**Business Owner Dept:** Renal Transplant	**Contract Number:** PONCS-19684 A3
Vendor/Supplier: Transplant Coordinators of America **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Sole Source Modification	Previous Board Approved Amount (06/22/2021):	$700,000
	Total amount of actions since last approval	
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$219,000
Original Start Date: 7/1/2021 **Last BOM Approval Date:** 6/22/2021 **Current Expiration:** 6/30/2026 **Mod Start Date:** 2/26/2026 **Expiration after this Mod:** 6/30/2026	New Board Approved Amount:	$919,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes
FTE Impact:	N/A

Submitted By (Division VP): Patricia Shirey, Vice President, Clinical Operations

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 On-Call Coverage for Patient Safety Officer and Clinical Post-Transplant Coordinator Services

VENDOR: Transplant Coordinators of America

COST:

Previous Board Approved Amount (06/22/2021):	$700,000
Actions since last approval	
Board amount requested # 1:	+ $219,000
Total:	$919,000

Recommendation
Approve this contract modification to On-Call Coverage for Patient Safety Officer and Clinical Post-Transplant Coordinator Services.

Background
A new regulatory requirement mandates that Parkland Health maintain a designated safety contact available 24/7. Since Transplant Coordinators of America (TCOA) already provides around-the-clock coverage for transplant services, this responsibility aligns with their existing operational structure and Parkland contract. Transplant Coordinators serve in a highly specialized capacity, and continuous coverage requires a formal contingency plan to address vacancies, FMLA, PTO, and other staffing gaps. To ensure uninterrupted compliance and operational readiness, it is necessary to have a PRN coordinator available to support these situations and maintain compliance.

Fair and Reasonable Price Determination
Market research conducted through ECRI shows no competitive data in the market for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	Total
$700,000	$219,000	$919,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source as determined by exhaustive market analysis and research by both Parkland and other trusted third-party services such as ECRI and Vizient.

Document Contact/Author:	Michelle Duffey

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Signatera Genetic Test	
Business Owner: Scott Hampton/Tim Lenz	**Business Owner Dept:** Laboratory Services – Referral Lab	**Contract Number:** POCS-20031
Vendor/Supplier/Contractor: Natera	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Prices Established by Law or Regulation

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	2/27/2026 – 3 years	$322,200
Out Years:	2 Year(s)	+$214,800
Total:	2/27/2026 – 2/26/2029	$537,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? Yes; and IT approved

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Submitted By (Division VP): Jenni Burnes Vice President, Ancillary Services, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Signatera Genetic Test

VENDOR: Natera

COST:

Base Term:	$322,200
Out Years:	+ $214,800
Total:	$537,000

Recommendation

Approve this contract for Signatera Genetic Test.

Background

This new contract adds Signatera to Pathology's genetic testing menu. Signatera is an advanced, highly sensitive assay for Molecular Residual Disease (MRD) that detects circulating tumor DNA (ctDNA). By analyzing ctDNA released into the bloodstream, the test determines the presence or absence of MRD and can identify relapse earlier than other methods. Natera is the sole provider of this technology.

Fair and Reasonable Price Determination

Pricing for the Signatera test is based on the patient's insurance status, including commercial insurance, Medicare, or Medicaid. Parkland patients who are uninsured or covered by Medicare or Medicaid and meet Natera's eligibility criteria will be enrolled in Natera's patient assistance program, which provides the test at no cost. If a patient does not qualify for the program, Natera will notify Parkland. Unless the District agrees to assume financial responsibility, the patient will be billed as a self-pay outpatient.

Financial Forecast

Base Term	FY2026	FY2027	FY2028	FY2029	FY2030	FY2031	Totals
Expenses / Consumables	$62,650	$107,400	$107,400	$44,750			$322,200
Out Years	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables				$62,650	$107,400	$44,750	$214,800
Grand Totals	**$62,650**	**$107,400**	**$107,400**	**$107,400**	**$107,400**	**$44,750**	**$537,000**

Sole Source Justification

Signatera (Natera) is the only option that covers multiple cancers (colorectal, bladder, breast, lung, ovarian, etc), and is covered by Medicare. Other options either have very limited indications or lack Medicare coverage.

Document Contact/Author:	Tamisha Smallwood

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Request Additional Funds for Blood and Blood Products	
Business Owner: Tim Lenz/Amy Sigman	**Business Owner Dept:** Laboratory Services - Transfusion Services	**Contract Number:** POCP-19129
Vendor/Supplier: BloodSolutions, LLC dba Bloodbuy **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Amount:	$196,000
	Total amount of actions since last approval	$0
Revenue, Expense or Capital: Expense	Current amount requested: # 1:	$250,000
Original Start Date: 3/7/2022 **Current Expiration:** Evergreen **Mod Start Date:** 3/25/2026 **Expiration after this Mod:** Evergreen	New Board Approved Amount:	$446,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Legal approved base document,
Does this modification have an IT Component?	amendment has no changes
Does this modification have a Construction Component?	No
	No

Financial

Is Funding included in the applicable FY Budget?	Yes
FTE Impact:	None

Submitted By (Division VP): Enrique Gallegos Senior Vice President Operations & Associate COO

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 Request Additional Funds for Blood and Blood Products

VENDOR: BloodSolutions, LLC dba Bloodbuy

COST:	Current Amount:	$196,000
	Actions since last approval	$0
	Board amount requested # 1:	+ $250,000
	Total:	$446,000

Recommendation

Approve this contract modification to Request Additional Funds for Blood and Blood Products.

Background

This contract is for Parkland's exchange participation with BloodSolutions dba Bloodbuy for blood and blood products. INTERCEPT Fibrinogen Complex (IFC) is a recently added blood product in Transfusion Services used to support patients with life-threatening hemorrhage that are on Massive Transfusion Protocol (MTP). Since implementation on August 11, utilization has consistently exceeded the original projection of 10 units per month. This increase reflects a higher volume of high acuity cases requiring MTP. As a result, additional funding is being requested to maintain adequate inventory levels to ensure continued availability.

Actual IFC Utilization

Month	Units Used
Aug-25	18
Sep-25	27
Oct-25	15
Nov-25	16
Dec-25	34
Jan-26	42

Fair and Reasonable Price Determination

Bloodbuy pricing is based on a transparent marketplace model where hospitals purchase blood and blood products at competitive, real-time prices set by participating blood centers, not by Bloodbuy itself. Bloodbuy does not charge hospitals for access to the platform; instead, it enables competitive bidding that typically lowers unit costs and improves fill rates.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
$196,000	$145,833	$104,167	$446,000

Sole Source Justification

Human Tissue - Skin, marrow, blood and blood products, heart valves, and/or other human organs are exempt products.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Alaris pump modules and associated software	
Business Owner: Patrick Eaton	**Business Owner Dept:** Clinical Engineering	**Contract Number:** POCP-26172
Vendor/Supplier/Contractor: Becton Dickinson CareFusion	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital and Expense

	Contract Dates	Contract Price
Base Term:	2/25/2026 – 1/31/2028	$843,879
Out Years:	0 Year(s)	+$0
Total:	2/25/2026 –1/31/2028	$843,879

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? Yes; approval in process

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Submitted By (Division VP): Lance Mendiola, Vice President, Construction, Facilities, Real Estate

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Alaris pump modules and associated software

VENDOR: Becton Dickinson CareFusion

COST:		
	Base Term:	$843,879
	Out Years:	+ $0
	Total:	$843,879

Recommendation
Approve this contract for Alaris pump modules and associated software.

Background
This contract is to purchase 112 Becton Dickinson Alaris Point of Care units, 224 Alaris pump modules, and associated software for the 8th and 9th floors as part of the Medical Surgery Expansion project. This equipment would be a bulk, capital purchase, adding to the current hospital fleet.

Fair and Reasonable Price Determination

The GPO contract and pricing were obtained in a solicitation process performed by Vizient. Market research conducted through ECRI shows that Parkland's price is XXX compared to other hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2026
Equipment / Licenses	$843,879

Document Contact/Author:	Michelle Duffey

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Central Utility Plant (CUP) Boiler Burner Replacement	
Business Owner: David Alvarez	**Business Owner Dept:** Engineering Services	**Contract Number:** PONCS-26046
Vendor/Supplier/Contractor: Burner Combustion Systems LLC	**Source Selection Methodology:** Invitation for Bids	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	2/26/2026 – 8/25/2026	$414,030
Out Years:	0 Year(s)	+$0
Total:	2/26/2026 – 8/25/2026	$414,030

Lowest Bidder

Is this contractor the lowest bidder/supplier? Yes
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Submitted By (Division VP): Lance Mendiola,Vice President, Construction, Facilities, Real Estate

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Central Utility Plant (CUP) Boiler Burner Replacement

VENDOR: Burner Combustion Systems LLC

COST:		
	Base Term:	$414,030
	Out Years:	+ $0
	Total:	$414,030

Recommendation
Approve this contract for Central Utility Plant (CUP) Boiler Burner Replacement.

Background
This contract is for the purchase and installation of two burners. The CUP at Parkland serves as the primary source of thermal energy for the hospital campus. The CUP houses six (6) dual-fueled boilers, which are essential for providing hot water and heating services to all patient care areas, administrative buildings, and ancillary facilities.

All six (6) boilers are equipped with Webster burner systems, which are no longer in production. The two boilers currently under discussion for burner replacement are configured as the primary units when the CUP transitions to alternate-fuel operation using #2 diesel. We will continue evaluating parts availability and OEM support while maintaining the remaining four units in their current configuration. The remaining four burners will require capital replacement in the future. These units were installed and commissioned in late 2011, with Parkland assuming ownership and operations in January 2012.

To ensure operational reliability and energy efficiency, it is recommended that these two outdated burners be replaced with new, high-efficiency units. Timely replacement will reduce the risk of unplanned outages, lower long-term operating costs, and support the hospital's mission to provide uninterrupted patient care in a safe and controlled environment.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition. An Invitation for Bid was issued, and three bids were received. The recommended vendor is the lowest-responsive bidder among the three.

Vendor	Price Differential
Burner Combustion	$0
Vendor B	$18,491
Vendor C	$39,644

Financial Forecast

Base Term	FY2026	Totals
Expenses	$414,030	$414,030

Document Contact/Author:	Steve Adrian

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 11 Eleventh Amendment to Lease Agreement	
Business Owner: Beall Carothers	**Business Owner Dept:** Planning Design & Construction	**Contract Number:** POCRE-19173.11
Vendor/Supplier: The Board of Regents of the University of Texas System for the use and benefit of the University of Texas Southwestern Medical Center at Dallas **Basis of Original Contract Award** Real Estate – Exemption **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (3-30-2021): OR, if has not been to the board, Current Contract Amount: Actions Totaling < $100,000 Amount: Amount: Amount:	$1,106,330 $ $ $
Revenue, Expense or Capital: Revenue: Court Approval	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 11 Amount:	$126,737
Original Start Date: 4/1/2008 **Current Expiration:** 3/31/2026 **Mod Start Date:** 4/1/2026 **Expiration after this Mod:** 3/31/2031	New Contract Amount:	$1,233,067

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Lance Mendiola, Vice President of Construction, Facilities, Real Estate, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 11 Eleventh Amendment to Lease Agreement

VENDOR: The Board of Regents of the University of Texas System for the use and benefit of the University of Texas Southwestern Medical Center at Dallas

COST:

BOM Approved Contract Total (3-30-2021): OR, if has not been to the board, Current Contract Amount:	$1,106,330
Action:	$
Action:	$
Action:	$
Modification # 11:	+ $126,737
Total:	$1,233,067

Recommendation
Approve this contract modification to Eleventh Amendment to Lease Agreement.

Background
UT Southwestern has operated a HIV Research Clinic at Parkland since April 2008. In June 2021, the clinic moved from the Amelia Court Building at the former Parkland campus to the Moody Outpatient Center ("MOC"). This lease amendment continues the lease relationship for the term of April 1, 2026, to March 31, 2031.

Either party may terminate the lease with 90 days written notice to the other party.

Fair and Reasonable Price Determination
Not applicable – real estate exemption. However, rental rates were confirmed through search of comparable properties through Costar (Commercial Real Estate database).

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	FY2029
$1,106,330	($8,781)	$29,099	$29,679	$30,272

FY2030	FY2031	Total
$30,878	$15,590	$1,233,067

As per the terms of the lease amendment, in FY 2026, Parkland will reimburse UTSW in the amount of $23,186.07 which represents rental amounts that were overcharged by Parkland to UTSW for the period of 6-15-2022 to 3-31-2026. The overcharged amount is the result of the premises in Moody building being mis-measured by Beck in 2022. In early 2022, Beck provided the UTSW lease space square footage of 1,573 square feet, but the actual measurement for the suite is 1,289 square feet. The difference is a 284 square foot discrepancy. Rental rate for the period of 6-15-22 to 3-31-26 (1,386 days total) is $21.50 per square foot. At a daily rental rate of $16.73 for 1,386 days, the resulting math is $23,186.07. Per the lease amendment, Parkland agrees to issue a check to UTSW within thirty (30) days from March 31, 2026.

Sole Source Justification
Not applicable – real estate exemption

Document Contact/Author:	Beall Carothers, Director Real Estate Development

Board Approval Request For Contracts Over $200,000

BOM Date: February 25, 2026	**Product or Service:** Bryte Assistive AI SaaS for UKG Pro WFM	
Business Owner: Deborah Johnson	**Business Owner Dept:** Information Technology	**Contract Number:** POIT-26105
Vendor/Supplier/Contractor: UKG Kronos Systems LLC	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	3/1/2026 – 2/28/2029	$867,000
Out Years:	0 Year(s)	+$
Total:	3/1/2026 – 2/28/2029	$867,000

Lowest Bidder

Is this contractor the lowest bidder/supplier?	N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder?	N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency?	Yes
Does this contract have an IT Component?	Yes; and IT approved
Does this contract have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Joe Longo, Senior Vice President & Chief Information Officer

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Bryte Assistive AI SaaS for UKG Pro WFM

VENDOR: UKG Kronos Systems LLC

COST:		
	Base Term:	$867,000
	Out Years:	+ $
	Total:	$867,000

Recommendation
Approve this contract for Bryte Assistive AI SaaS for UKG Pro WFM.

Background
This contract supports the implementation of an AI-driven application designed to enhance organizational decision-making. In alignment with this fiscal year's strategic focus on expanding AI capabilities, we conducted a review of existing solutions and identified that UKG offers Bryte AI Agents, a native integration within Information Technologies' current UKG Pro suite. Adopting Bryte AI Agents will enable teams across Parkland's organization to leverage advanced artificial intelligence to improve workplace experiences, streamline people-centric processes, and drive more informed, efficient decision-making.

Fair and Reasonable Price Determination
Although this procurement is a sole-source purchase, the proposed pricing is considered fair and reasonable based on several factors. The pricing aligns with UKG's established commercial rate structure for similar modules and enhancements within the Pro platform. Additionally, the cost is consistent with prior UKG purchases for comparable proprietary functionality, demonstrating price stability over time. The proposed amount is deemed fair and reasonable.

Financial Forecast

Base Term	FY2026	FY2027	FY2028	Totals
Licenses/Services	$289,000	$289,000	$289,000	$867,000

Sole Source Justification
This purchase qualifies as a sole-source procurement due to the proprietary nature of the application and its required integration. Bryte AI Agents is a UKG-developed, proprietary solution available exclusively within the UKG Pro suite. No third-party vendors are authorized to provide, license, or support this technology, and no alternative products can integrate with Information Technologies' existing UKG environment at the required level of functionality or security. Due to these proprietary limitations, UKG is the only vendor capable of delivering the application, ensuring compatibility with Parkland's current systems and maintaining ongoing support.

Document Contact/Author:	Farrah Smith

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) – External Audit	
Business Owner: Mandy Transou	**Business Owner Dept:** HIM Coding Integrity	**Contract Number:** PONCS-24251 A2
Vendor/Supplier: Health Information Associates **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total 4/23/2025	$2,407,440
	Actions Totaling < $100,000 Amount: Amount: Amount:	$83,000
Revenue, Expense, or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 1 Amount:	$80,000
Original Start Date: 5/1/2025 **Current Expiration:** 4/30/2028 **Mod Start Date:** Last Signature **Expiration after this Mod:** 4/30/2028	New Contract Amount:	$2,570,440

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Gerry Baker, Senior Vice President, Revenue Cycle

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) – External Audit

VENDOR: Health Information Associates

COST:

BOM Approved Contract Total 4/23/2025	$2,407,440
Modification:	$83,000
Modification:	
Modification:	
Modification # 1:	+ $80,000
Total:	$2,570,440

Recommendation

Approve this contract modification to Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) – External Audit.

Background

Parkland currently contracts for Health Information Management (HIM) Quality Coding and Clinical Documentation Integrity (CDI) External Audit Services to ensure the accuracy, completeness, and the compliance of provider documentation and billed charges. As part of ongoing efforts to strengthen revenue integrity and reduce financial and regulatory risk, Parkland is seeking to expand the scope of its physician quality audits. At present, external audits of providers' billed charges are conducted twice per year. However, increasing audit frequency to four times per year will allow for more timely identification of documentation gaps, coding errors, and potential charge risks. Quarterly audits will also support earlier intervention to prevent denials, improve coding quality, and enhance overall compliance with billing standards. This request reflects Parkland's commitment to maintaining high quality documentation practices and safeguarding the organization against preventable revenue loss.

The additional $80,000 is to cover the cost of the additional provider audits.

Fair and Reasonable Price Determination

A fair and reasonable price was determined through adequate competition.

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	FY2029	FY2030	Total
$2,407,440	$496,610	$496,610	$511,250	$525,710	$540,260	$2,570,440

Document Contact/Author:	Baruh Bosch

Board Approval Request For Modification to Contract or Funding

BOM Date: February 25, 2026	**Modification:** Mod # 1 Consulting Services for Affordable Care Act (ACA) Exchange Plan	
Business Owner: Kristin Alvarez	**Business Owner Dept:** Value-Based Care	**Contract Number:** PONCS-24546 A2
Vendor/Supplier: Milliman, Inc. **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (10/30/2024): Actions Totaling < $100,000 Amount:	1,290,000
Revenue, Expense, or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 1 Amount:	$1,600,000
Original Start Date: 11/1/2024 **Current Expiration:** 11/30/2026 **Mod Start Date:** 2/25/2026 **Expiration after this Mod:** 11/30/2026	New Contract Amount:	$2,890,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Submitted By (Division VP): Monal Shah, SVP Chief Clin Transf Officer

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 Consulting Services for Affordable Care Act (ACA) Exchange Plan

VENDOR: Milliman, Inc.

COST:

BOM Approved Contract Total (10/30/2024):	1,290,000
Action:	
Action:	
Action:	
Modification # 1:	+ $1,600,000
Total:	$2,890,000

Recommendation
Approve this contract modification to Consulting Services for Affordable Care Act (ACA) Exchange Plan.

Background
In November 2025, it was determined that the anticipated time to complete the consulting services for the ACA Strategy Engagement, which includes operational design, planning and implementation, would require an extension. Under the guidance and direction of senior leadership, the initial term of the contract was extended additional 1 year. The initial engagement scope consisted of two parts: providing an analysis and recommendation reports for optimization of existing contracts/revenue cycle and feasibility of an ACA Exchange Plan. The revenue cycle work is nearly complete. This contract extension period covers the implementation phase of the Affordable Care Act (ACA) Exchange Plan, including, but not limited to, the following: TDI licensing in 2026; QHP licensing in 2027 to allow enrollment starting in November 2027; PBM and off-exchange exploration; and product development. This work is currently accounted for in the FY 2026 budget. It builds directly on the data, insights, and stakeholder consensus generated in the initial engagement, allowing the District to move efficiently into execution. The funds will cover the restated 2026 services through the extension period.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
1,290,000	$1,280,000	$320,000	$2,890,000

Document Contact/Author:	Gracy Thomas

Parkland

Approved Deviation Request
New Contract

Must be approved before: February 17, 2026	**Reason for deviation request:** An immediate start to the consulting services is essential to ensure Parkland can rapidly address emerging financial pressures and operational risks.

BOM Date: March 25, 2026	**Product or Service:** Consulting Services for Children's Health Impact Assessment & Improvement Actions, and Parkland Health Plan Contribution Margin Improvement.	
Business Owner: Edmundo Castaneda	**Business Owner Dept:** Administration	**Contract Number:** PONCS-26221
Vendor/Supplier/Contractor: Shara McClure Health Solutions	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense-Approved Deviation

	Contract Dates	Contract Price
Base Term:	2/13/2026 – 8/12/2026	$650,000
Out Years:	0 Year(s)	+$0
Total:	2/13/2026 – 8/12/2026	$650,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Submitted By (Division VP): Fred Cerise, MD, President and Chief Executive Officer

Request: Authorize the appropriate Contracting Officer to execute this contract with the stipulation that it will be presented to the Parkland Board of Managers for approval at the next regularly scheduled meeting.

Fred Cerise

Fred Cerise (Feb 13, 2026 13:38:19 CST) **Date:** 02/13/2026

Dr. Fred Cerise, President & CEO

RFMA

RFMA (Feb 13, 2026 13:51:06 CST) **Date:** 02/13/2026

Chair Finance Committee

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Consulting Services for Children's Health Impact Assessment & Improvement Actions, and Parkland Health Plan Contribution Margin Improvement.

VENDOR: Shara McClure Health Solutions

COST:

Base Term:	$650,000
Out Years:	+ $0
Total:	$650,000

Recommendation

Approve this contract for Consulting Services for Children's Health Impact Assessment & Improvement Actions, and Parkland Health Plan Contribution Margin Improvement..

Approved Deviation Reason

This contract provides consulting support to help Parkland develop and drive execution of financial-viability strategies related to the Children's Health contract and contribution-margin improvement opportunities.

The work outlined in this engagement directly supports critical decisions tied to cost management, contract performance, and long-term financial stability. Any postponement would slow the analysis and actions needed to stabilize the health plan, putting Parkland at greater risk of continued financial deterioration and limiting its ability to respond proactively. Immediate execution ensures the consulting team can begin work without interruption and deliver insights in time to inform upcoming strategic and budgetary decisions.

Background

Parkland acquiring these consulting services to address mounting financial and operational pressures that cannot be resolved with existing internal capacity alone. The Children's Health contract and contribution-margin performance present complex challenges that demand specialized expertise, rapid analysis, and targeted action.

Engaging external support ensures Parkland can quickly identify root causes, validate opportunities, and implement strategies that strengthen financial sustainability. Without this engagement, critical decisions would be delayed, risks would continue to grow, and Parkland's ability to stabilize and improve plan performance would be significantly constrained.

Fair and Reasonable Price Determination

An internal analysis of prior solicitations for comparable consulting engagements was conducted to establish a fair and reasonable price determination, ensuring alignment with historical market benchmarks and organizational procurement standards.

Financial Forecast

Base Term	FY2026
Expenses / Consumables	$650,000

Sole Source Justification

The services provided are very specialized consulting services and obtaining these services through the competitive process is not practical nor is it in the best interest of Parkland.
There is an immediate and serious need for the services and resort to the normal procurement methods would cause such a delay as to threaten District resources (i.e., it's an emergency procurement because of the health plan's current financial situation).

Document Contact/Author:	Terence Durham

CONTRACT RESOLUTION
Board of Managers
February 25, 2026

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requested approval for certain contracts and approval/rejection is as checked below:

Approved	Rejected	Withdrawn	Type	Service or Product	Vendor	Contract Term	Aggregate Contract Amount Approved	Budgeted
			Expense	Mod # 1 Two-Year Contract Extension for Mycobacteria Growth Indicator Tube (MGIT) Reagents	Becton and Dickinson and Company	3/20/2023 - 3/19/2028	$85,000	Yes
			Expense	Biomet Microfixation, LLC Craniomaxillofacial (CMF) and Thoracic Fixation Systems	Biomet Microfixation, LLC	2/25/2026 – 2/24/2029	$850,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Coronary Stents and Accessories	Boston Scientific	3/1/2026 – 2/28/2031	$2,250,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	EchoTip Insight Portosystemic Pressure Gradient Measuring System	Cook Medical, Inc	2/25/2026 – 2/26/2031	$350,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Adding Additional Funding for Genetic Testing Services through Exact Sciences	Exact Sciences Laboratories, LLC	1/29/2024 - 2/28/2027	$170,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Add Funding for Genetic Testing through Foundation Medicine Inc.	Foundation Medicine Inc.	3/28/2024 - 4/30/2026	$500,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Capital	Cardiac Stress Systems	GE Healthcare	3/6/2026 – 3/5/2027	$222,824	Yes
			Expense	Mod # 3 Neurosurgical Implants	Integra LifeSciences	1/1/2021-12/31/2027	$1,401,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 One Year Contract Extension for OCD Diana Reagents	Polymedco Cancer Diagnostic Produ	3/1/2023 - 2/28/2027	$270,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Neurovascular Implants	Stryker Neurovascular	1/1/2019 -12/31/2026	$361,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 5 Biotel Emergency Medical Services	The University of Texas Southweste	10/16/2016 - 9/30/2026	$134,480	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 On-Call Coverage for Patient Safety Officer and Clinical Post Transplant Coordinator Services	Transplant Coordinators of America	7/1/2021- 6/30/2026	$219,000	Yes
			Expense	Signatera Genetic Test	Natera	2/27/2026 – 2/26/2029	$537,000	Yes
			Expense	Mod # 1 Request Additional Funds for Blood and Blood Products	BloodSolutions, LLC dba Bloodbuy	3/7/2022 - Evergreen	$446,000	Yes
			Capital and Expense	Alaris Pump Modules, and associated software	BD CareFusion	2/25/2026 –1/31/2028	$843,880	Yes

			Capital	Central Utility Plant (CUP) Boiler Burner Replacement	Burner Combustion Systems LLC	2/26/2026 – 8/25/2026	$414,030	Yes
			Revenue: Court Approval	The Board of Regents of the University of Texas System for the use and benefit of the University of Texas Southwestern Medical Center at Dallas	Mod # 11 Eleventh Amendment to L	4/1/2008 - 3/31/2031	$126,737	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Bryte Assistive AI SaaS for UKG Pro WFM	UKG Kronos Systems LLC	3/1/2026 – 2/28/2029	$867,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Health Information Management (HIM) Quality Coding & Clinical Documentation Integrity (CDI) – External Audit	Health Information Associates	5/1/2025 - 4/30/2028	$80,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Consulting Services for Affordable Care Act (ACA) Exchange	Milliman, Inc.	11/1/2024 - 11/31/2026	$1,600,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves these contracts as noted.

Dated this 25th of February 2026.

_____
Vincent Hall
Chair

_____
Brad Nitschke JD
Assistant Secretary

Marjorie Petty, JD Yes _____ No _____ Abstain _____ Absent _____
Jeff Tillotson, JD Yes _____ No _____ Abstain _____ Absent _____
Todd Furniss, JD Yes _____ No _____ Abstain _____ Absent _____
Eric G. Bing, MD, PhD Yes _____ No _____ Abstain _____ Absent _____
Byron Cryer, MD Yes _____ No _____ Abstain _____ Absent _____
Reina Gonzalez, JD Yes _____ No _____ Abstain _____ Absent _____
Vincent Hall Yes _____ No _____ Abstain _____ Absent _____
Ramon Miguez, PE Yes _____ No _____ Abstain _____ Absent _____
Farida Minner, RN Yes _____ No _____ Abstain _____ Absent _____
Miriam Sharma, RN Yes _____ No _____ Abstain _____ Absent _____
Yasmin Simon, JD Yes _____ No _____ Abstain _____ Absent _____

Consideration and Appropriate Action Regarding Fiscal 8311-1-20 Retirement Plan Funding Policy

DALLAS COUNTY HOSPITAL DISTRICT
RETIREMENT INCOME PLAN

FUNDING POLICY
~~(Adopted)~~(Adopted November 20, 2019; Revised January [ ], 2026~~Revised~~)

Recitals:

A. Dallas County Hospital District, also known as Parkland Health ("Parkland"), provides its eligible employees a defined benefit retirement plan called the "Dallas County Hospital District Retirement Income Plan" (the "Retirement Income Plan").

B. The Retirement Income Plan was originally effective January 1, 1982.

C. The purpose of the Retirement Income Plan is to provide retirement and other related benefits to those Parkland employees who are eligible to participate in the Retirement Income Plan.

D. The Retirement Income Plan was most recently amended and restated in its entirety effective January 1, 20~~1~~24 (the "20~~1~~24 Restatement").

E. ~~As per the Plan's~~ Under the terms of the 2024 Restatement of the Retirement Income Plan, employees who were active full-time employees of Parkland or an affiliated employer before December 13, 2023 are eligible to participate in the Retirement Income Plan provided that they continue in active full-time employment status. Full-time employees who are hired or re-hired as full-time or who transfer to a full-time position after December 12, 2023 are not eligible to participate in the Retirement Income Plan ~~all full-time employees hired or moved from part-time status after December 12, 2023 will be ineligible to participate in the Retirement Income Plan~~ and will, instead, be enrolled in Parkland's ~~the~~ Mandatory Savings Plan, a defined contribution plan administered with Parkland's Supplemental Savings Plans.

F. Pursuant to the requirements of S.B. No. 2224, which amended Section 802.2011 of the Texas Government Code, effective September 1, 2019, Parkland's Board of Managers (the "Board"), as the applicable governing body of the Retirement Income Plan, is required to do the following:

1. adopt a written funding policy that details Parkland's plan for achieving a funded ratio of the Retirement Income Plan that is equal to or greater than 100 percent;

2. maintain for public review at its main office a copy of the policy; and

3. file a copy of the policy and each change to the policy with the Texas Pension Review Board not later than the 31st day after the date the policy or change, as applicable is adopted.

~~F~~G. The term "public retirement system" is defined in Section 802.001 of the Texas Government Code as a continuing, organized program of service retirement, disability retirement,

or death benefits for officers or employees of the state or a political subdivision, or of an agency or instrumentality of the state or a political subdivision, subject to certain other exceptions and exclusions. The Retirement Income Plan is a public retirement system and is subject to the requirements of S.B. No. 2224.

~~G~~H. The funded ratio of the Retirement Income Plan is as set forth below as ~~reported in the Guide to Public Retirement Systems in Texas published for the 86th Legislature, March 2019, by the Texas Pension Review Board and available at https://www.prb.state.tx.us/txpen/wp-content/uploads/2019/03/2019-Legislative-Guide-Final.pdf:~~calculated by the Retirement Income Plan's actuary each year:

Valuation Date	Funded Ratio
1/1/2013	80.00%
1/1/2014	82.53%
1/1/2015	76.35%
1/1/2016	74.91%
1/1/2017	73.76%
1/1/2018	73.41%
1/1/2019	71.53%
1/1/2020	64.81%
1/1/2021	68.78%
1/1/2022	73.~~16~~33%
1/1/2023	72.90%
1/1/2024	73.57%
1/1/2025	72.94%

~~H~~I. Parkland's Board now desires to adopt the proposal set forth herein to comply with S.B. No. 2224 and to memorialize Parkland's funding goals for the Retirement Income Plan.

NOW, THEREFORE, Parkland's Board hereby adopts the following Funding Policy for the Retirement Income Plan:

I. Purpose and Scope.

This Funding Policy memorializes actuarial assumptions and methodologies and the long-term funding goals for the Retirement Income Plan. This Funding Policy is effective for actuarial valuations performed on and after January 1, 202~~2~~5. Parkland's Board has also used this opportunity to establish guidelines to ensure that the Retirement Income Plan is well-funded into the future.

II. Definitions.

"**Actual Employer Contribution**" means the actual contributions paid by Parkland in accordance with the terms of the Retirement Income Plan document.

"**Actuarial Liability**" means the actuarial accrued liability determined in accordance with the actuarial assumptions and methods set forth in Section IV of this Funding Policy.

"**Actuarial Value of Plan Assets**" means the Retirement Income Plan's assets determined in accordance with the actuarial assumptions and methods set forth in Section IV of this Funding Policy.

"**Actuarially Determined Contribution**" means Parkland's theoretical periodic contribution to the Retirement Income Plan. The Actuarially Determined Contribution includes Parkland's normal cost and a provision for amortizing the Unfunded Liability. The Actuarially Determined Contribution is the amount that Parkland would need to fund each year in order to pre-fund the Actuarial Liability and build the funds necessary to fully finance the benefits over time.

"**Board of Managers**" means the Board of Managers of the Dallas County Hospital District, also known as Parkland Health ~~& Hospital System~~.

"**Funding Period**" means the length of time required to eliminate the Retirement Income Plan's Actuarial Liability.

"**Funded Ratio**", with respect to the Retirement Income Plan, means the Actuarial Value of Plan Assets expressed as a percentage of the Actuarial Liability.

"**Retirement Income Plan**" means the Dallas County Hospital District Retirement Income Plan as in effect from time to time.

"**Unfunded Liability**" means the Actuarial Liability of the Retirement Income Plan in excess of the Actuarial Value of Plan Assets.

III. STATEMENT OF INTENT.

Parkland intends to fund the Retirement Income Plan sufficiently to preserve the ability of the Retirement Income Plan to reliably pay benefits promised under the terms and conditions of the Retirement Income Plan to current and future retirees and beneficiaries.

IV. ACTUARIAL ASSUMPTIONS AND METHODS.

A. The Board has reviewed and adopted the following actuarial assumptions and methods for the purposes of actuarial valuations and plan funding:

1. Asset Valuation Method – 5-year Smoothing

2. Actuarial Cost Method – Entry Age Normal

3. Amortization Method – Level Percent over a closed period of ~~22~~19 years, as of January 1, 202~~2~~5. It is the intent of the Board that the Funded Ratio of the Retirement Income Plan will be 100% on or before January 1, 2044.

4. Discount Rate – 6.00% for the plan year beginning January 1, 2020.

5. Inflation Rate – 3.00%

6. Mortality Table – 2024 Adjusted MP-2021 Projection Scale projected for the plan year beginning January 1, 2025

B. The Retirement Income Plan's actuarial assumptions and methods are to be periodically reviewed by the actuary and by Parkland's Treasury Director and its Chief Financial Officer, and they shall make recommendations to the Board concerning any changes to the actuarial assumptions and methods. Actuarial assumptions and methods should be compared to actual experience and future expectations.

V. EMPLOYEE CONTRIBUTIONS AND EMPLOYER CONTRIBUTIONS.

A. Employee Contributions. Pursuant to the terms of the Retirement Income Plan, eligible employees are required to contribute 6.2% of their respective annual earnings to the Retirement Income Plan each year.

B. Employer Contributions. Parkland intends to contribute an amount determined each year by the Board.

VI. ACTUARY.

The Board has engaged Milliman USA as the actuary for the Retirement Income Plan. In addition to other responsibilities, Milliman is responsible during the term of its engagement to provide an actuarial valuation of the benefit cost and funded status relating to the retirement benefits provided by the Retirement Income Plan for each plan year. Any termination or engagement of an actuary is subject to the approval of the Board.

VII. DETERMINATION OF EMPLOYER CONTRIBUTION; EXCEPTIONS.

A. The policy of Parkland is to fund contributions by Parkland to the Retirement Income Plan each year in an amount no less than the Actuarially Determined Contribution. The Board may approve exceptions to this policy upon request made by Parkland's Chief Executive Officer, after consultation with Parkland's Chief Financial Officer and Treasury Director, and any such request shall include a detailed description of the circumstances making consideration of an exception necessary.

B. The actuarial assumptions and methods set forth in Section IV above (and all other material assumptions taken into consideration in the determination of the Actuarially Determined Contribution) have been reviewed and adopted by the Board. No change in actuarial assumptions and methods (and any other material assumptions) will be made without the express written approval of the Board.

VIII. AMENDMENTS TO RETIREMENT INCOME PLAN.

This Funding Policy has been adopted by the Board based on the provisions of the Retirement Income Plan as currently in effect. Amendments to the Retirement Income Plan must be reviewed and adopted by Parkland's Board, which shall consider the impact that a proposed amendment may have on this Funding Policy. In the event of any conflict between the provisions of the Retirement Income Plan, as in effect from time to time, and the provisions of this Funding Policy, the provisions of this Funding Policy shall govern and the conflicting provisions of the Retirement Income Plan shall be considered to have been amended by the provisions of this Funding Policy to the extent necessary to resolve the conflict.

IX. AMENDMENTS TO THIS FUNDING POLICY.

The Board may amend this Funding Policy. Any such amendment must be in writing at the time of the vote by the Board. Amendments to this Funding Policy are subject to the disclosure and filing requirements of S.B. No. 2224 which are summarized above.

X. ACTION BY BOARD.

Any action required in this Funding Policy to be taken by Parkland's Board shall be taken at such time and in such manner as to constitute the lawful act of the Board. Parkland's Board may delegate all or part of its authority to act hereunder in such manner as it considers reasonable and appropriate to carry out the intent of this Funding Policy; provided, however, that no such delegation shall be effective unless the terms and conditions of such delegation are in writing at the time that the Board acts to grant such delegation. The acts of the delegate, to the extent consistent with and in the scope of the written delegation, shall be considered the acts of Parkland's Board.

ADOPTED by the Board of Managers of the Dallas County Hospital District ~~on:~~ _____.

_____

~~Marjorie Petty, JD~~Vincent Hall
~~Chairwoman~~Chairman
Board of Managers
Dallas County Hospital District

_____

~~Steven J. Roth~~Brad Nitschke

~~Executive Vice President & General~~ Interim Chief Counsel
Assistant Secretary
Dallas County Hospital District

DALLAS COUNTY HOSPITAL DISTRICT
RETIREMENT INCOME PLAN

FUNDING POLICY
(Adopted November 20, 2019; Revised February 25, 2026)

Recitals:

A. Dallas County Hospital District, also known as Parkland Health ("Parkland"), provides its eligible employees a defined benefit retirement plan called the "Dallas County Hospital District Retirement Income Plan" (the "Retirement Income Plan").

B. The Retirement Income Plan was originally effective January 1, 1982.

C. The purpose of the Retirement Income Plan is to provide retirement and other related benefits to those Parkland employees who are eligible to participate in the Retirement Income Plan.

D. The Retirement Income Plan was most recently amended and restated in its entirety effective January 1, 2024 (the "2024 Restatement").

E. Under the terms of the 2024 Restatement of the Retirement Income Plan, employees who were active full-time employees of Parkland or an affiliated employer before December 13, 2023 are eligible to participate in the Retirement Income Plan provided that they continue in active full-time employment status. Full-time employees who are hired or re-hired as full-time or who transfer to a full-time position after December 12, 2023 are not eligible to participate in the Retirement Income Plan and will, instead, be enrolled in Parkland's Mandatory Savings Plan, a defined contribution plan administered with Parkland's Supplemental Savings Plans.

F. Pursuant to the requirements of S.B. No. 2224, which amended Section 802.2011 of the Texas Government Code, effective September 1, 2019, Parkland's Board of Managers (the "Board"), as the applicable governing body of the Retirement Income Plan, is required to do the following:

1. adopt a written funding policy that details Parkland's plan for achieving a funded ratio of the Retirement Income Plan that is equal to or greater than 100 percent;

2. maintain for public review at its main office a copy of the policy; and

3. file a copy of the policy and each change to the policy with the Texas Pension Review Board not later than the 31st day after the date the policy or change, as applicable is adopted.

G. The term "public retirement system" is defined in Section 802.001 of the Texas Government Code as a continuing, organized program of service retirement, disability retirement, or death benefits for officers or employees of the state or a political subdivision, or of an agency

or instrumentality of the state or a political subdivision, subject to certain other exceptions and exclusions. The Retirement Income Plan is a public retirement system and is subject to the requirements of S.B. No. 2224.

H. The funded ratio of the Retirement Income Plan is as set forth below as calculated by the Retirement Income Plan's actuary each year:

Valuation Date	Funded Ratio
1/1/2013	80.00%
1/1/2014	82.53%
1/1/2015	76.35%
1/1/2016	74.91%
1/1/2017	73.76%
1/1/2018	73.41%
1/1/2019	71.53%
1/1/2020	64.81%
1/1/2021	68.78%
1/1/2022	73.33%
1/1/2023	72.90%
1/1/2024	73.57%
1/1/2025	72.94%

I. Parkland's Board now desires to adopt the proposal set forth herein to comply with S.B. No. 2224 and to memorialize Parkland's funding goals for the Retirement Income Plan.

NOW, THEREFORE, Parkland's Board hereby adopts the following Funding Policy for the Retirement Income Plan:

I. Purpose and Scope.

This Funding Policy memorializes actuarial assumptions and methodologies and the long-term funding goals for the Retirement Income Plan. This Funding Policy is effective for actuarial valuations performed on and after January 1, 2025. Parkland's Board has also used this opportunity to establish guidelines to ensure that the Retirement Income Plan is well-funded into the future.

II. Definitions.

"**Actual Employer Contribution**" means the actual contributions paid by Parkland in accordance with the terms of the Retirement Income Plan document.

"**Actuarial Liability**" means the actuarial accrued liability determined in accordance with the actuarial assumptions and methods set forth in Section IV of this Funding Policy.

"**Actuarial Value of Plan Assets**" means the Retirement Income Plan's assets determined in accordance with the actuarial assumptions and methods set forth in Section IV of this Funding Policy.

"**Actuarially Determined Contribution**" means Parkland's theoretical periodic contribution to the Retirement Income Plan. The Actuarially Determined Contribution includes Parkland's normal cost and a provision for amortizing the Unfunded Liability. The Actuarially Determined Contribution is the amount that Parkland would need to fund each year in order to pre-fund the Actuarial Liability and build the funds necessary to fully finance the benefits over time.

"**Board of Managers**" means the Board of Managers of the Dallas County Hospital District, also known as Parkland Health.

"**Funding Period**" means the length of time required to eliminate the Retirement Income Plan's Actuarial Liability.

"**Funded Ratio**", with respect to the Retirement Income Plan, means the Actuarial Value of Plan Assets expressed as a percentage of the Actuarial Liability.

"**Retirement Income Plan**" means the Dallas County Hospital District Retirement Income Plan as in effect from time to time.

"**Unfunded Liability**" means the Actuarial Liability of the Retirement Income Plan in excess of the Actuarial Value of Plan Assets.

III. STATEMENT OF INTENT.

Parkland intends to fund the Retirement Income Plan sufficiently to preserve the ability of the Retirement Income Plan to reliably pay benefits promised under the terms and conditions of the Retirement Income Plan to current and future retirees and beneficiaries.

IV. ACTUARIAL ASSUMPTIONS AND METHODS.

A. The Board has reviewed and adopted the following actuarial assumptions and methods for the purposes of actuarial valuations and plan funding:

1. Asset Valuation Method – 5-year Smoothing

2. Actuarial Cost Method – Entry Age Normal

3. Amortization Method – Level Percent over a closed period of 19 years, as of January 1, 2025. It is the intent of the Board that the Funded Ratio of the Retirement Income Plan will be 100% on or before January 1, 2044.

4. Discount Rate – 6.00% for the plan year beginning January 1, 2020.

5. Inflation Rate – 3.00%

6. Mortality Table – 2024 Adjusted MP-2021 Projection Scale projected for the plan year beginning January 1, 2025

B. The Retirement Income Plan's actuarial assumptions and methods are to be periodically reviewed by the actuary and by Parkland's Treasury Director and its Chief Financial Officer, and they shall make recommendations to the Board concerning any changes to the actuarial assumptions and methods. Actuarial assumptions and methods should be compared to actual experience and future expectations.

V. EMPLOYEE CONTRIBUTIONS AND EMPLOYER CONTRIBUTIONS.

A. Employee Contributions. Pursuant to the terms of the Retirement Income Plan, eligible employees are required to contribute 6.2% of their respective annual earnings to the Retirement Income Plan each year.

B. Employer Contributions. Parkland intends to contribute an amount determined each year by the Board.

VI. ACTUARY.

The Board has engaged Milliman as the actuary for the Retirement Income Plan. In addition to other responsibilities, Milliman is responsible during the term of its engagement to provide an actuarial valuation of the benefit cost and funded status relating to the retirement benefits provided by the Retirement Income Plan for each plan year. Any termination or engagement of an actuary is subject to the approval of the Board.

VII. DETERMINATION OF EMPLOYER CONTRIBUTION; EXCEPTIONS.

A. The policy of Parkland is to fund contributions to the Retirement Income Plan each year in an amount no less than the Actuarially Determined Contribution. The Board may approve exceptions to this policy upon request made by Parkland's Chief Executive Officer, after consultation with Parkland's Chief Financial Officer and Treasury Director, and any such request shall include a detailed description of the circumstances making consideration of an exception necessary.

B. The actuarial assumptions and methods set forth in Section IV above (and all other material assumptions taken into consideration in the determination of the Actuarially Determined Contribution) have been reviewed and adopted by the Board. No change in actuarial assumptions and methods (and any other material assumptions) will be made without the express written approval of the Board.

VIII. AMENDMENTS TO RETIREMENT INCOME PLAN.

This Funding Policy has been adopted by the Board based on the provisions of the Retirement Income Plan as currently in effect. Amendments to the Retirement Income Plan must be reviewed and adopted by Parkland's Board, which shall consider the impact that a proposed amendment may have on this Funding Policy. In the event of any conflict between the provisions of the Retirement Income Plan, as in effect from time to time, and the provisions of this Funding Policy, the provisions of this Funding Policy shall govern and the conflicting provisions of the Retirement Income Plan shall be considered to have been amended by the provisions of this Funding Policy to the extent necessary to resolve the conflict.

IX. AMENDMENTS TO THIS FUNDING POLICY.

The Board may amend this Funding Policy. Any such amendment must be in writing at the time of the vote by the Board. Amendments to this Funding Policy are subject to the disclosure and filing requirements of S.B. No. 2224 which are summarized above.

X. ACTION BY BOARD.

Any action required in this Funding Policy to be taken by Parkland's Board shall be taken at such time and in such manner as to constitute the lawful act of the Board. Parkland's Board may delegate all or part of its authority to act hereunder in such manner as it considers reasonable and appropriate to carry out the intent of this Funding Policy; provided, however, that no such delegation shall be effective unless the terms and conditions of such delegation are in writing at the time that the Board acts to grant such delegation. The acts of the delegate, to the extent consistent with and in the scope of the written delegation, shall be considered the acts of Parkland's Board.

ADOPTED by the Board of Managers of the Dallas County Hospital District on:_____.

_____
Vincent Hall
Chairman
Board of Managers
Dallas County Hospital District

_____
Brad Nitschke
Interim Chief Counsel
Assistant Secretary
Dallas County Hospital District

Consideration and Appropriate Action Regarding Parkland's PCCI Board of Directors Reappointment of Dick Daniels

PCCI Board Member Approval

Action requested: Approval of the PCCI Board of Directors' recommendation for the reappointment of Dick Daniels to a three-year term on the PCCI Board of Directors.

Background: The PCCI Board of Directors voted unanimously to recommend Mr. Daniels for an additional three-year term commencing in March 2026. This term is within the maximum years of service permitted by the PCCI Amended and Restated Bylaws ("PCCI Bylaws"). Mr. Daniels has served on the PCCI Board since February 2018 and continues to contribute significant expertise in data and technology, healthcare innovation, and strategic and financial performance.

Governance: Under the PCCI Bylaws, the PCCI Board recommends prospective new and renewing directors to the Parkland Board of Managers through the PCCI Secretary. After review and consideration, the Parkland Board may approve, modify, or reject the PCCI Board's recommendation.

Consideration and Appropriate Action Regarding Patient Settlements

Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of _____YES and ____ NAY, does by this resolution (adopt/reject) _____the following:

WHEREAS, the Medical Executive Committee recommends approval of the Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers as presented.

THEREFORE BE IT RESOLVED that the Board of Managers approves the recommended Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers.

Dated this 25th of February 2026

_____ _____

Vincent Hall, Chair

Brad Nitschke, JD, Assistant Secretary

Marjorie D. Petty, JD	Yes_____ No_____ Abstain _____Absent_____
Miriam Sharma, RN	Yes_____ No_____ Abstain _____Absent_____
Todd Furniss, JD Eric	Yes_____ No_____ Abstain _____Absent_____
G. Bing, MD, PhD	Yes_____ No_____ Abstain _____Absent_____
Byron Cryer, MD	Yes_____ No_____ Abstain _____Absent_____
Reina Gonzalez, JD	Yes_____ No_____ Abstain _____Absent_____
Vincent Hall	Yes_____ No_____ Abstain _____Absent_____
Ramon Miguez, PE	Yes_____ No_____ Abstain _____Absent_____
Farida Minner, RN	Yes_____ No_____ Abstain _____Absent_____
Jeff Tillotson, JD	Yes_____ No_____ Abstain _____Absent_____
Yasmin Simon, JD	Yes_____ No_____ Abstain _____Absent_____

CEO Update on System Operations

FIFA Update and Disaster Management Presentation

Governance Update and Discussion Regarding Key Upcoming Dates and Board Committee Appointments

Break

Executive Session

Discussion Regarding Potential New Service Lines and Property Acquisition

Consultation with Attorney on Risks Identified and Considered by the Governance, Compliance and Ethics Committee in the Quarterly Report on Open Compliance Reviews Covered in their February 11, 2026 Meeting Tex. Gov't Code 551.071

Executive Session Documents

Possible Deliberation Regarding Medical Executive Committee Credentialing Report

Executive Session Documents

Possible Deliberation Regarding Delineation of Privileges Internal Medicine – Nephrology

Executive Session Documents

Possible Deliberation Regarding Delineation of Privileges OB/GYN

Executive Session Documents

Possible Deliberation Regarding Delineation of Privileges Hematology & Medical Oncology

Executive Session Documents

Possible Deliberation Regarding Patient Settlements

Possible Deliberation Regarding Board of Managers Attendance Report

Possible Deliberation Regarding Board of Managers Meeting Evaluation Report